<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) - Ni, H - 2018 | Cochrane Library</title> <meta content="Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) - Ni, H - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011594.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) - Ni, H - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011594.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011594.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)" name="citation_title"/> <meta content="Han Ni" name="citation_author"/> <meta content="SEGi University" name="citation_author_institution"/> <meta content="hanni.dr@gmail.com" name="citation_author_email"/> <meta content="Soe Moe" name="citation_author"/> <meta content="Melaka Manipal Medical College" name="citation_author_institution"/> <meta content="Zay Soe" name="citation_author"/> <meta content="UCSI University" name="citation_author_institution"/> <meta content="Kay Thi Myint" name="citation_author"/> <meta content="Faculty of Medicine, SEGi University" name="citation_author_institution"/> <meta content="K Neelakantan Viswanathan" name="citation_author"/> <meta content="P K Das Institute of Medical Sciences" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011594.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/12/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011594.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011594.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011594.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta-2 Receptor Agonists [*therapeutic use]; Bronchodilator Agents [therapeutic use]; Disease Progression; Drug Therapy, Combination [methods]; Dyspnea [drug therapy]; Forced Expiratory Volume; Formoterol Fumarate [therapeutic use]; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; Tropanes [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011594.pub2&amp;doi=10.1002/14651858.CD011594.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011594\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011594\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011594.pub2",title:"Combined aclidinium bromide and long\\u2010acting beta2\\u2010agonist for chronic obstructive pulmonary disease (COPD)",firstPublishedDate:"Dec 11, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011594.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011594.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011594.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011594.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011594.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011594.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011594.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011594.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011594.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011594.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3161 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011594.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-sec-0113"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-sec-0107"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/appendices#CD011594-sec-0118"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/table_n/CD011594StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/table_n/CD011594StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#CD011594-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Han Ni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#CD011594-cr-0003">Soe Moe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#CD011594-cr-0004">Zay Soe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#CD011594-cr-0005">Kay Thi Myint</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information#CD011594-cr-0006">K Neelakantan Viswanathan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information/en#CD011594-sec-0128">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 December 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011594.pub2">https://doi.org/10.1002/14651858.CD011594.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011594-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011594-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011594-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011594-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011594-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011594-abs-0001" lang="en"> <section id="CD011594-sec-0001"> <h3 class="title" id="CD011594-sec-0001">Background</h3> <p>Several dual bronchodilator combinations of long‐acting beta<sub>2</sub>‐agonist (LABA) and long‐acting muscarinic antagonist (LAMA) have been approved for treatment of stable chronic obstructive pulmonary disease (COPD). The current GOLD (Global Initiative for Chronic Obstructive Lung Disease) recommendations suggest the use of LABA/LAMA combinations in people with group B COPD with persistent symptoms, group C COPD with further exacerbations on LAMA therapy alone and group D COPD with or without inhaled corticosteroids (ICS). Fixed‐dose combination (FDC) of aclidinium/formoterol is one of the approved LABA/LAMA therapies for people with stable COPD. </p> </section> <section id="CD011594-sec-0002"> <h3 class="title" id="CD011594-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of combined aclidinium bromide and long‐acting beta<sub>2</sub>‐agonists in stable COPD. </p> </section> <section id="CD011594-sec-0003"> <h3 class="title" id="CD011594-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register (CAGR), ClinicalTrials.gov, World Health Organization (WHO) trials portal, United States Food and Drug Administration (FDA) and manufacturers' websites as well as the reference list of published trials up to 12 October 2018. </p> </section> <section id="CD011594-sec-0004"> <h3 class="title" id="CD011594-sec-0004">Selection criteria</h3> <p>Parallel‐group randomised controlled trials (RCTs) assessing combined aclidinium bromide and LABAs in people with stable COPD. </p> </section> <section id="CD011594-sec-0005"> <h3 class="title" id="CD011594-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane for data collection and analysis. The primary outcomes were exacerbations requiring a short course of an oral steroid or antibiotic, or both; quality of life measured by a validated scale and non‐fatal serious adverse events (SAEs). Where the outcome or study details were not reported, we contacted the study investigators or pharmaceutical company trial co‐ordinators (or both) for missing data. </p> </section> <section id="CD011594-sec-0006"> <h3 class="title" id="CD011594-sec-0006">Main results</h3> <p>We identified RCTs comparing aclidinium/formoterol FDC versus aclidinium, formoterol or placebo only. We included seven multicentre trials of four to 52 weeks' duration conducted in outpatient settings. There were 5921 participants, whose mean age ranged from 60.7 to 64.7 years, mostly men with a mean smoking pack‐years of 46.4 to 61.3 of which 43.9% to 63.4% were current smokers. They had a moderate‐to‐severe degree of COPD with a mean postbronchodilator forced expiratory volume in one second (FEV<sub>1</sub>) between 50.5% and 61% of predicted normal and the baseline mean FEV<sub>1</sub> of 1.23 L to 1.43 L. We assessed performance and detection biases as low for all studies whereas selection, attrition and reporting biases were either low or unclear. </p> <p><b>FDC versus aclidinium</b> </p> <p>There was no evidence of a difference between FDC and aclidinium for exacerbations requiring steroids or antibiotics, or both (OR 0.95, 95% CI 0.71 to 1.27; 2 trials, 2156 participants; moderate‐certainty evidence); quality of life measured by St George's Respiratory Questionnaire (SGRQ) total score (MD –0.92, 95% CI –2.15 to 0.30); participants with significant improvement in SGRQ score (OR 1.17, 95% CI 0.97 to 1.41; 2 trials, 2002 participants; moderate‐certainty evidence); non‐fatal SAE (OR 1.19, 95% CI 0.79 to 1.80; 3 trials, 2473 participants; moderate‐certainty evidence); hospital admissions due to severe exacerbations (OR 0.62, 95% CI 0.29 to 1.29; 2 trials, 2156 participants; moderate‐certainty evidence) or adverse events (OR 0.95, 95% CI 0.76 to 1.18; 3 trials, 2473 participants; moderate‐certainty evidence). Compared with aclidinium, FDC improved symptoms (Transitional Dyspnoea Index (TDI) focal score: MD 0.37, 95% CI 0.07 to 0.68; 2 trials, 2013 participants) with a higher chance of achieving a minimal clinically important difference (MCID) of at least one unit improvement (OR 1.34, 95% CI 1.11 to 1.62; high‐certainty evidence); the number needed to treat for an additional beneficial outcome (NNTB) being 14 (95% CI 9 to 39). </p> <p><b>FDC versus formoterol</b> </p> <p>When compared to formoterol, combination therapy reduced exacerbations requiring steroids or antibiotics, or both (OR 0.78, 95% CI 0.62 to 0.99; 3 trials, 2694 participants; high‐certainty evidence); may decrease SGRQ total score (MD –1.88, 95% CI –3.10 to –0.65; 2 trials, 2002 participants; low‐certainty evidence; MCID for SGRQ is 4 units); increased TDI focal score (MD 0.42, 95% CI 0.11 to 0.72; 2 trials, 2010 participants) with more participants attaining an MCID (OR 1.30, 95% CI 1.07 to 1.56; high‐certainty evidence) and an NNTB of 16 (95% CI 10 to 60). FDC lowered the risk of adverse events compared to formoterol (OR 0.78, 95% CI 0.65 to 0.93; 5 trials, 3140 participants; high‐certainty evidence; NNTB 22). However, there was no difference between FDC and formoterol for hospital admissions, all‐cause mortality and non‐fatal SAEs. </p> <p><b>FDC versus placebo</b> </p> <p>Compared with placebo, FDC demonstrated no evidence of a difference in exacerbations requiring steroids or antibiotics, or both (OR 0.82, 95% CI 0.60 to 1.12; 2 trials, 1960 participants; moderate‐certainty evidence) or hospital admissions due to severe exacerbations (OR 0.55, 95% CI 0.25 to 1.18; 2 trials, 1960 participants; moderate‐certainty evidence), although estimates were uncertain. Quality of life measure by SGRQ total score was significantly better with FDC compared to placebo (MD –2.91, 95% CI –4.33 to –1.50; 2 trials, 1823 participants) resulting in a corresponding increase in SGRQ responders who achieved at least four units decrease in SGRQ total score (OR 1.72, 95% CI 1.39 to 2.13; high‐certainty evidence) with an NNTB of 7 (95% CI 5 to 12). FDC also improved symptoms measured by TDI focal score (MD 1.32, 95% CI 0.96 to 1.69; 2 studies, 1832 participants) with more participants attaining at least one unit improvement in TDI focal score (OR 2.51, 95% CI 2.02 to 3.11; high‐certainty evidence; NNTB 4). There were no differences in non‐fatal SAEs, adverse events and all‐cause mortality between FDC and placebo. </p> <p>Combination therapy significantly improved trough FEV<sub>1</sub> compared to aclidinium, formoterol or placebo. </p> </section> <section id="CD011594-sec-0007"> <h3 class="title" id="CD011594-sec-0007">Authors' conclusions</h3> <p>FDC improved dyspnoea and lung function compared to aclidinium, formoterol or placebo, and this translated into an increase in the number of responders on combination treatment. Quality of life was better with combination compared to formoterol or placebo. There was no evidence of a difference between FDC and monotherapy or placebo for exacerbations, hospital admissions, mortality, non‐fatal SAEs or adverse events. Studies reported a lower risk of moderate exacerbations and adverse events with FDC compared to formoterol; however, larger studies would yield a more precise estimate for these outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011594-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011594-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011594-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011594-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011594-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011594-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011594-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011594-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011594-abs-0004" lang="en"> <h3>Are combined aclidinium and long‐acting beta2‐agonist inhalers effective and safe for people with stable COPD? </h3> <p><b>Background</b> </p> <p>Chronic obstructive pulmonary disease (COPD) is a disease of the lungs that causes airways to narrow. As a result, people with COPD experience symptoms of breathlessness and cough with sputum production which worsen over time. It is mainly caused by smoking or inhaling dust. In people with COPD, inhalers that contain medicines to widen the airways are generally given to relieve symptoms. Long‐acting medicines whose action lasts for at least half a day or one day are preferred. Aclidinium and formoterol (a long‐acting beta<sub>2</sub>‐agonist medicine) are such inhalers. We wanted to find out how a combination of aclidinium and long‐acting beta<sub>2</sub>‐agonist fare against either inhaler alone and dummy (placebo) inhaler. </p> <p><b>Study characteristics</b> </p> <p>We could only identify studies on aclidinium and formoterol combination and included seven studies involving 5921 people with COPD which ranged from four weeks to one year long. Most participants were men in their 60s, moderate‐to‐heavy smokers, around half of whom were current smokers. They had moderate‐to‐severe symptoms of COPD when they started treatment. People in the studies took either combined inhalers containing aclidinium and formoterol or aclidinium or formoterol or placebo through a similar inhaler. Both people doing the research and people in the study did not know which treatment participants were getting. The conclusions of this review are current to October 2018. </p> <p><b>Key results</b> </p> <p>People taking combined inhaler and aclidinium inhaler were not different in terms of flare‐ups that need additional medicines, quality of life, hospitalisations, side effects or serious side effects. However, they were less breathless than those taking aclidinium inhaler. Fourteen people with COPD would need to be treated with combined inhalers to have one additional person with a clinically significant improvement in breathlessness. </p> <p>People on combined inhalers were likely to have fewer flare‐ups, side effects and symptoms and a better quality of life compared to those taking formoterol inhaler. But, there was little or no difference in hospital admissions due to severe flare‐ups, serious side effects or the risk of dying. </p> <p>When compared to dummy inhalers, people taking combined inhalers experienced less breathlessness and better quality of life. Seven people with COPD would need to be treated with combined inhaler to achieve a significant improvement in quality of life than dummy inhaler. For flare‐ups, hospital admissions, side effects, serious side effects and death, there was no difference between combined and dummy inhalers. </p> <p>The lungs worked better in people taking combined inhalers than those taking only one drug or dummy inhaler. </p> <p><b>Quality of the evidence</b> </p> <p>We had to interpret the results carefully as all the included studies were sponsored by pharmaceutical companies, which could have led to bias. However, the included studies were generally conducted in a systematic and acceptable manner. We are confident that combined inhalers are more effective than single or dummy inhalers at improving breathlessness and lung function. However, we are less certain about its effects on flare‐ups, hospital admissions, quality of life and side effects. </p> <p><b>Conclusion</b> </p> <p>Combined inhalers are more effective than individual or dummy inhalers for relieving breathlessness and improving lung performance. They also lead to better quality of life than formoterol or dummy inhalers. However, they are not different from individual or dummy inhalers in terms of flare‐ups or hospital admissions. These combined inhalers have similar safety profiles as individual or dummy inhalers in terms of death, side effects or serious side effects. Combined inhalers probably had lesser side effects and moderate flare‐ups than formoterol, but further studies are needed to confidently support this finding. In summary, the combined inhalers are an effective option for treatment of COPD and appear to have a similar safety profile to individual or dummy inhalers. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011594-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011594-sec-0113">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011594-sec-0177">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011594-sec-0113"></div> <h3 class="title" id="CD011594-sec-0114">Implications for practice</h3> <section id="CD011594-sec-0114"> <p>Combination treatment with aclidinium/formoterol provides improvements in lung function and dyspnoea across all comparisons with aclidinium, formoterol or placebo as well as a better health‐related quality of life than formoterol or placebo. However, some uncertainty remains regarding its superiority over aclidinium alone for improvement in quality of life. Therefore, combined therapy is an appropriate treatment for people with confirmed symptomatic stable chronic obstructive pulmonary disease (COPD). Current evidence is insufficient to confirm the effects of aclidinium/formoterol combination on the chances of experiencing an exacerbation or hospital admissions for exacerbations. As there is no evidence of a difference in mortality or non‐fatal serious adverse events compared with monotherapies or placebo, fixed‐dose combination of aclidinium/formoterol could be considered a relatively safe option for treating people with stable COPD. </p> </section> <h3 class="title" id="CD011594-sec-0115">Implications for research</h3> <section id="CD011594-sec-0115"> <p>Further research is indicated to clarify potential differences in efficacy between aclidinium/formoterol and alternative LABA/LAMA combinations, particularly with respect to quality of life, dyspnoea and exacerbations. Trialists should define and report exacerbations consistently and, if possible, provide disaggregated data for participants in different COPD severity groups. Longer‐term follow‐up data would be beneficial, especially to identify any impact of combined aclidinium/formoterol on exacerbations, hospital admissions, serious adverse events and mortality. Further trials examining the efficacy and safety of aclidinium/formoterol with participant‐related outcomes as primary endpoints rather than lung function improvement would be more appropriate for applicability to clinical practice in people with COPD. Studies on cost‐effectiveness comparing aclidinium/formoterol with other available combinations of LABA/LAMA are also anticipated. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011594-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011594-sec-0022"></div> <div class="table" id="CD011594-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to aclidinium alone for chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fixed‐dose combination aclidinium/formoterol compared to aclidinium for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> FDC aclidinium/formoterol<br/> <b>Comparison:</b> aclidinium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with aclidinium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FDC aclidinium/formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids or antibiotics or both: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (77 to 130) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.95</b><br/> (0.71 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2156<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>579 per 1000<br/> (533 to 624) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.17</b><br/> (0.97 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: change from baseline in SGRQ total score was 0.92 lower (2.15 lower to 0.3 higher) in FDC group (2002 participants, 2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (33 to 72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.19</b><br/> (0.79 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2473<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (5 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.62</b><br/> (0.29 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2156<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)</b> <br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>557 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>627 per 1000<br/> (582 to 671) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.34</b><br/> (1.11 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms: change from baseline in TDI focal score was 0.37 higher (0.07 higher to 0.68 higher) in FDC group (2013 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in lung function: from baseline in trough FEV<sub>1</sub> (L)</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) across aclidinium group ranged from –0.017 to 0.066 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) in the FDC group was 0.02 higher (0 to 0.04 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2333<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (not including serious adverse events): number of participants</b> </p> <p>Follow‐up: 4–24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000<br/> (155 to 221) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.95</b><br/> (0.76 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2473<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FDC:</b> fixed‐dose combination; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>TDI:</b> Transitional Dyspnoea Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision: the CIs included a potential for appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011594-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to formoterol for chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fixed‐dose combination aclidinium/ formoterol compared to formoterol for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> FDC aclidinium/formoterol<br/> <b>Comparison:</b> formoterol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with formoterol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FDC aclidinium/formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids or antibiotics or both: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000<br/> (101 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b><br/> (0.62 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2694<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>524 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>559 per 1000<br/> (495 to 623) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.15</b><br/> (0.89 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: change from baseline in SGRQ total score was 1.88 lower (3.1 lower to 0.65 lower) in FDC group (2002 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b><br/> Follow‐up: 4–52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (42 to 79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.15</b><br/> (0.82 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3140<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations: number of participants</b><br/> Follow‐up: 24–52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (12 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.76</b><br/> (0.45 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2694<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>565 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000<br/> (582 to 670) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.30</b><br/> (1.07 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms: change from baseline in TDI focal score was 0.42 higher (0.11 higher to 0.72 higher) in FDC group (2010 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in lung function: from baseline in trough FEV<sub>1</sub> (L)</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) across formoterol group ranged from –0.002 to 0.118 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) in the FDC group was 0.04 higher (0.03 higher to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2411<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (not including serious adverse events): number of participants</b><br/> Follow‐up: 4–52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (195 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b><br/> (0.65 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3140<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FDC:</b> fixed‐dose combination; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>TDI:</b> Transitional Dyspnoea Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision: CIs included a potential for appreciable benefit or harm. </p> <p><sup>b</sup>Downgraded one level as <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> did not report the SGRQ responders for formoterol arm in the published articles. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011594-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to placebo for chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fixed dose combination aclidinium/formoterol compared to placebo for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic obstructive pulmonary disease (COPD)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> FDC aclidinium/formoterol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FDC aclidinium/formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids or antibiotics or both: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/> (82 to 143) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b><br/> (0.60 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1960<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000<br/> (515 to 619) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.72</b><br/> (1.39 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1823<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: change from baseline in SGRQ total score was 2.91 lower (4.33 lower to 1.5 lower) in FDC group (1823 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/> (27 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.12</b><br/> (0.72 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2527<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (5 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.55</b><br/> (0.25 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1960<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000<br/> (568 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.51</b><br/> (2.02 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1832<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms: change from baseline in TDI focal score was 1.32 higher (0.96 higher to 1.69 higher) in FDC group (1832 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in lung function: from baseline in trough FEV<sub>1</sub> (L)</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) across placebo group ranged from –0.061 to –0.031 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) in the FDC group was 0.12 higher (0.10 higher to 0.14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2137<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (not including serious adverse events): number of participants</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/> (139 to 206) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.97</b><br/> (0.76 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2527<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FDC:</b> fixed‐dose combination; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>TDI:</b> Transitional Dyspnoea Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision: the CIs included a potential for appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011594-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011594-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011594-sec-0138">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011594-sec-0023"></div> <section id="CD011594-sec-0024"> <h3 class="title" id="CD011594-sec-0024">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is characterised by slowly progressive airflow limitation that is not fully reversible and is associated with enhanced inflammatory response of the airways and destruction of lung parenchyma (<a href="./references#CD011594-bbs2-0027" title="BarnesPJ . Chronic obstructive pulmonary disease. New England Journal of Medicine2000;343(4):269‐80. [PUBMED: 10911010] ">Barnes 2000</a>; <a href="./references#CD011594-bbs2-0042" title="CrinerGJ , BourbeauJ , DiekemperRL , OuelletteDR , GoodridgeD , HernandezP , et al. Prevention of acute exacerbations of chronic obstructive pulmonary disease: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest2015; Vol. 147, issue 4:894‐942. [PUBMED: 25321320] ">Criner 2015</a>; <a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). It is the fourth leading cause of death in Canada and the third in the US, with 12.7 million adults in the US estimated to have COPD in 2011 (<a href="./references#CD011594-bbs2-0042" title="CrinerGJ , BourbeauJ , DiekemperRL , OuelletteDR , GoodridgeD , HernandezP , et al. Prevention of acute exacerbations of chronic obstructive pulmonary disease: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest2015; Vol. 147, issue 4:894‐942. [PUBMED: 25321320] ">Criner 2015</a>). As the result of continued exposure to smoking and environmental pollution, COPD is projected to become the third leading cause of death worldwide by 2020 (<a href="./references#CD011594-bbs2-0039" title="ChapmanKR , ManninoDM , SorianoJB , VermeirePA , BuistAS , ThunMJ , et al. Epidemiology and costs of chronic obstructive pulmonary disease. European Respiratory Journal2006;27(1):188‐207. [PUBMED: 16387952] ">Chapman 2006</a>; <a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>; <a href="./references#CD011594-bbs2-0079" title="RaherisonC , GirodetPO . Epidemiology of COPD. European Respiratory Review2009;18(114):213‐21. [PUBMED: 20956146] ">Raherison 2009</a>). Well‐described COPD prevalence of approximately 15% among smokers is considered to be an underestimate caused by underdiagnosis (<a href="./references#CD011594-bbs2-0081" title="RennardSI , VestboJ . COPD: the dangerous underestimate of 15%. Lancet2006;367(9518):1216‐9. [PUBMED: 16631861] ">Rennard 2006</a>), and is noted to be as high as 50% among heavy smokers according to current criteria (<a href="./references#CD011594-bbs2-0064" title="ManninoDM , BuistAS . Global burden of COPD: risk factors, prevalence, and future trends. Lancet2007;370(9589):765‐73. [PUBMED: 17765526] ">Mannino 2007</a>). Active smoking remains the major risk factor for COPD, posing a serious health threat to more than 1.1 billion smokers worldwide (<a href="./references#CD011594-bbs2-0029" title="BauerCM , MorissetteMC , StampfliMR . The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. Chest2013;143(1):196‐206. [PUBMED: 23276842] ">Bauer 2013</a>). However, non‐smokers are also affected by COPD, with a prevalence of 3% to 11% reported among never‐smokers (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). In one population‐based study of lifelong never‐smokers, risk of COPD was independently associated with passive smoking or environmental tobacco smoke (<a href="./references#CD011594-bbs2-0055" title="HagstadS , BjergA , EkerljungL , BackmanH , LindbergA , RonmarkE , et al. Passive smoking exposure is associated with increased risk of COPD in never smokers. Chest2014;145(6):1298‐304. [PUBMED: 24356778] ">Hagstad 2014</a>). Other factors such as exposure to biomass fuels and indoor air pollution are important causes of COPD in low‐ to middle‐income countries (<a href="./references#CD011594-bbs2-0033" title="BruceN , Perez‐PadillaR , AlbalakR . Indoor air pollution in developing countries: a major environmental and public health challenge. Bulletin of the World Health Organization2000;78(9):1078‐92. [PUBMED: 11019457] ">Bruce 2000</a>; <a href="./references#CD011594-bbs2-0083" title="RiveraRM , CosioMG , GhezzoH , SalazarM , Perez‐PadillaR . Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. International Journal of Tuberculosis and Lung Disease2008;12(8):972‐7. [PUBMED: 18647460] ">Rivera 2008</a>). </p> <p>The chronic airflow limitation in COPD is caused by a mixture of small airways disease (obstructive bronchiolitis) and parenchymal destruction (emphysema) (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). Destruction of alveoli and lung parenchyma by inflammatory infiltrates results in enlargement of air spaces, thus reducing the elastic pressure that generates expiratory flow (<a href="./references#CD011594-bbs2-0041" title="CosioMG , SaettaM , AgustiA . Immunologic aspects of chronic obstructive pulmonary disease. New England Journal of Medicine2009;360(23):2445‐54. [PUBMED: 19494220] ">Cosio 2009</a>; <a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). Onset of symptoms usually occurs when forced expiratory volume in one second (FEV<sub>1</sub>) has fallen to approximately 50% of predicted normal value (<a href="./references#CD011594-bbs2-0088" title="SutherlandER , CherniackRM . Management of chronic obstructive pulmonary disease. New England Journal of Medicine2004;350(26):2689‐97. [PUBMED: 15215485] ">Sutherland 2004</a>). </p> <p>Exacerbations of COPD are a major cause of morbidity and mortality; an exacerbation is defined as "an acute event characterised by worsening of the patient's respiratory symptoms that is beyond normal day‐to‐day variations and leads to a change in medication" (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). Respiratory viral and bacterial infections mainly precipitate exacerbations, which are associated with worsened quality of life, increased healthcare costs, accelerated decline in lung function and reduced survival (<a href="./references#CD011594-bbs2-0029" title="BauerCM , MorissetteMC , StampfliMR . The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. Chest2013;143(1):196‐206. [PUBMED: 23276842] ">Bauer 2013</a>; <a href="./references#CD011594-bbs2-0065" title="MarchettiN , CrinerGJ , AlbertRK . Preventing acute exacerbations and hospital admissions in COPD. Chest2013;143(5):1444‐54. [PUBMED: 23648908] ">Marchetti 2013</a>; <a href="./references#CD011594-bbs2-0070" title="MullerovaH , MaselliDJ , LocantoreN , VestboJ , HurstJR , WedzichaJ , et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest2015; Vol. 147, issue 4:999‐1007. [PUBMED: 25356881] ">Mullerova 2015</a>). Exacerbations may occur at any stage of COPD; however, the frequency of exacerbations correlates with the severity of airflow limitation, with a mean rate of 1.34 events/year in people with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 3 disease and 2.00 events/year in people with GOLD stage 4 disease (<a href="./references#CD011594-bbs2-0065" title="MarchettiN , CrinerGJ , AlbertRK . Preventing acute exacerbations and hospital admissions in COPD. Chest2013;143(5):1444‐54. [PUBMED: 23648908] ">Marchetti 2013</a>). One three‐year prospective observational study including 2138 participants reported severe exacerbations requiring hospital admission in about 30% of participants, causing a substantial economic burden (<a href="./references#CD011594-bbs2-0070" title="MullerovaH , MaselliDJ , LocantoreN , VestboJ , HurstJR , WedzichaJ , et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest2015; Vol. 147, issue 4:999‐1007. [PUBMED: 25356881] ">Mullerova 2015</a>). The long‐term prognosis of people with exacerbation‐related hospitalisations is poor, with mortality rates of 26% at two years and 55% at five years (<a href="./references#CD011594-bbs2-0065" title="MarchettiN , CrinerGJ , AlbertRK . Preventing acute exacerbations and hospital admissions in COPD. Chest2013;143(5):1444‐54. [PUBMED: 23648908] ">Marchetti 2013</a>; <a href="./references#CD011594-bbs2-0070" title="MullerovaH , MaselliDJ , LocantoreN , VestboJ , HurstJR , WedzichaJ , et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest2015; Vol. 147, issue 4:999‐1007. [PUBMED: 25356881] ">Mullerova 2015</a>). </p> <p>The major goals of treatment in stable COPD are to relieve symptoms, reduce exacerbations, and improve quality of life and exercise tolerance (<a href="./references#CD011594-bbs2-0026" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179‐91. ">ATS/ERS 2011</a>; <a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>; <a href="./references#CD011594-bbs2-0088" title="SutherlandER , CherniackRM . Management of chronic obstructive pulmonary disease. New England Journal of Medicine2004;350(26):2689‐97. [PUBMED: 15215485] ">Sutherland 2004</a>; <a href="./references#CD011594-bbs2-0092" title="YangIA , BrownJL , GeorgeJ , JenkinsS , McDonaldCF , McDonaldV , et al. The COPD‐X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2018. Version 2.53, March 2018. www.copdx.org.au/ (accessed 10 July 2018). ">TSANZ 2018</a>). Bronchodilators are the cornerstone for symptomatic treatment of stable COPD (<a href="./references#CD011594-bbs2-0089" title="TashkinDP , CooperCB . The role of long‐acting bronchodilators in the management of stable COPD. Chest2004;125(1):249‐59. [PUBMED: 14718448] ">Tashkin 2004</a>); inhaled long‐acting bronchodilators (both beta<sub>2</sub>‐agonists and anticholinergics) are more effective than short‐acting bronchodilators in sustaining symptom relief (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). Some evidence suggests that early initiation of long‐acting bronchodilator therapy in mild‐to‐moderate cases of stable COPD may impact lung function decline and health‐related quality of life (HRQoL) (<a href="./references#CD011594-bbs2-0095" title="WelteT , VogelmeierC , PapiA . COPD: early diagnosis and treatment to slow disease progression. International Journal of Clinical Practice2015; Vol. 69, issue 3:336‐49. [DOI: 10.1111/ijcp.12522; PUBMED: 25363328] ">Welte 2015</a>). However, inhaled corticosteroids (ICSs) in early disease have no impact on lung function (<a href="./references#CD011594-bbs2-0095" title="WelteT , VogelmeierC , PapiA . COPD: early diagnosis and treatment to slow disease progression. International Journal of Clinical Practice2015; Vol. 69, issue 3:336‐49. [DOI: 10.1111/ijcp.12522; PUBMED: 25363328] ">Welte 2015</a>), and long‐term monotherapy is not recommended for stable COPD (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). ICSs are indicated as long‐term therapy only for people with severe‐to‐very severe airflow limitation who experience frequent exacerbations despite using long‐acting bronchodilators (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>; <a href="./references#CD011594-bbs2-0092" title="YangIA , BrownJL , GeorgeJ , JenkinsS , McDonaldCF , McDonaldV , et al. The COPD‐X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2018. Version 2.53, March 2018. www.copdx.org.au/ (accessed 10 July 2018). ">TSANZ 2018</a>). Current guidelines recommend combination therapy of inhaled long‐acting beta<sub>2</sub>‐agonists (LABAs) and long‐acting muscarinic antagonists (LAMAs) as an alternative choice for people with moderate‐to‐severe stable COPD if no symptomatic improvement is seen with use of a single agent (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). As the result of complementary and independent mechanisms for bronchodilation, combined LAMA/LABA therapy provides significantly greater improvement in lung function compared with LAMA or LABA monotherapy in people with moderate‐to‐severe COPD (<a href="./references#CD011594-bbs2-0037" title="CazzolaM , MolimardM . The scientific rationale for combining long‐acting beta2‐agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics2010;23(4):257‐67. [PUBMED: 20381630] ">Cazzola 2010</a>; <a href="./references#CD011594-bbs2-0090" title="TashkinDP , CelliB , DecramerM , LiuD , BurkhartD , CassinoC , et al. Bronchodilator responsiveness in patients with COPD. European Respiratory Journal2008;31(4):742‐50. [PUBMED: 18256071] ">Tashkin 2008</a>; <a href="./references#CD011594-bbs2-0094" title="van derMolenT , CazzolaM . Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient‐centred outcomes. Primary Care Respiratory Journal2012;21(1):101‐8. [PUBMED: 22222945] ">van der Molen 2012</a>); however, impact on patient‐reported outcomes is limited (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). </p> </section> <section id="CD011594-sec-0025"> <h3 class="title" id="CD011594-sec-0025">Description of the intervention</h3> <section id="CD011594-sec-0026"> <h4 class="title">Aclidinium bromide</h4> <p>Aclidinium bromide is a long‐acting anticholinergic that blocks the action of the neurotransmitter acetylcholine. It has potent antagonistic effects on all muscarinic acetylcholine receptor subtypes (M1 to M5) (<a href="./references#CD011594-bbs2-0093" title="UlrikCS . Aclidinium bromide: clinical benefit in patients with moderate to severe COPD. Open Respiratory Medicine Journal2012;6:150‐4. ">Ulrik 2012</a>); however, only M2 and M3 subtypes are present on airway smooth muscles (<a href="./references#CD011594-bbs2-0069" title="MoultonBC , FryerAD . Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. British Journal of Pharmacology2011;163:44‐52. ">Moulton 2011</a>). Acetylcholine‐induced bronchoconstriction is mediated mainly by M3 receptors and indirectly by M2 receptors, which prevent beta<sub>2</sub>‐adrenergic receptor‐mediated bronchial relaxation through inhibition of adenylate cyclase (<a href="./references#CD011594-bbs2-0069" title="MoultonBC , FryerAD . Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. British Journal of Pharmacology2011;163:44‐52. ">Moulton 2011</a>). M2 receptors also mediate feedback inhibition of acetylcholine release at the cholinergic nerve endings (<a href="./references#CD011594-bbs2-0059" title="KarakiulakisG , RothM . Muscarinic receptors and their antagonists in COPD: anti‐inflammatory and anti‐remodeling effects. www.ncbi.nlm.nih.gov/pmc/articles/PMC3512336/ (accessed 16 November 2014). ">Karakiulakis 2012</a>; <a href="./references#CD011594-bbs2-0086" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. ">Sims 2011</a>). Aclidinium dissociates more slowly from the M3 receptor than from the M2 receptor because of its approximately six‐fold kinetic selectivity for the M3 compared with the M2 subtype, leading to more effective bronchodilator action with lesser M2‐mediated cardiac adverse effects (<a href="./references#CD011594-bbs2-0063" title="MaltaisF , MilotJ . The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease2012;6(6):345‐61. ">Maltais 2012</a>; <a href="./references#CD011594-bbs2-0086" title="SimsMW , PanettieriRAJr . Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease2011;6:457‐66. ">Sims 2011</a>). </p> <p>Aclidinium has been approved as twice‐daily maintenance therapy in stable COPD (<a href="./references#CD011594-bbs2-0048" title="Food , DrugAdministration . Drug approval package; Tudorza Pressair (aclidinium bromide) inhalation powder. www.accessdata.fda.gov/drugsatfda_docs/label/.../202450s000lbl.pdf (accessed 15 November 2014). ">FDA 2012</a>). In one Cochrane Review (<a href="./references#CD011594-bbs2-0074" title="NiH , SoeZ , MoeS . Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2] ">Ni 2014</a>), aclidinium reduced the number of participants with exacerbation‐related hospitalisations compared with placebo (odds ratio (OR) 0.64, 95% confidence interval (CI) 0.46 to 0.88). Within the same review, aclidinium was also associated with significant benefit over placebo in HRQoL, breathlessness and lung function indices. Aclidinium produced no significant reduction in exacerbations requiring a short course of an oral steroid or antibiotic, or both. However, there was no strong evidence to support the superiority of aclidinium over the current standard of care, tiotropium or LABAs (<a href="./references#CD011594-bbs2-0074" title="NiH , SoeZ , MoeS . Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2] ">Ni 2014</a>). </p> </section> <section id="CD011594-sec-0027"> <h4 class="title">Long‐acting beta<sub>2</sub>‐agonists </h4> <p>Inhaled LABAs are widely used as maintenance therapy for people with COPD with moderate‐to‐severe airflow limitation and as an alternative therapy for people with mild disease (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). Twice‐daily salmeterol and formoterol have been in clinical use since the late 1990s, and once‐daily preparations of LABAs with an even longer duration of action have become available to improve adherence (<a href="./references#CD011594-bbs2-0098" title="ZafarMA , DroegeC , FoertschM , PanosRJ . Update on ultra‐long‐acting beta agonists in chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs2014;23(12):1687‐701. [PUBMED: 25139313] ">Zafar 2014</a>). Indacaterol is the first once‐daily LABA approved for clinical use by the US Food and Drug Administration (FDA) and it was approved in July 2011 (<a href="./references#CD011594-bbs2-0047" title="Food , DrugAdministration . FDA approved drug products: Arcapta neohaler (indacaterol inhalation powder). www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s002lbl.pdf (accessed 24 November 2014). ">FDA 2011</a>). This was followed by approvals of combined preparations of once‐daily LABA with ICS or LAMA. The FDA‐approved the vilanterol–fluticasone furoate combination in May 2013 (<a href="./references#CD011594-bbs2-0049" title="Food , DrugAdministration . FDA approved drug products: Breo Ellipta (fluticasone furoate and vilanterol inhalation powder). www.accessdata.fda.gov/drugsatfda_docs/label/2013/204275s000lbl.pdf (accessed 24 November 2014). ">FDA 2013a</a>), and the vilanterol–umeclidinium combination in December 2013 (<a href="./references#CD011594-bbs2-0050" title="Food , DrugAdministration . Drug approval package: Ellipta (umeclidinium /vilanterol) powder for inhalation. www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203975Orig1s000TOC.cfm (accessed 2 December 2014). ">FDA 2013b</a>), as once‐daily, long‐term maintenance treatment of people with stable COPD. </p> <p>Beta<sub>2</sub>‐receptors are located mainly in bronchial smooth muscle, while beta<sub>1</sub>‐receptors are situated predominantly in the heart. However, beta<sub>2</sub>‐receptors in the heart account for approximately 10% to 50% of the total beta‐receptors of the heart, and this results in the likelihood of cardiac adverse effects, even with highly selective beta<sub>2</sub>‐agonists (<a href="./references#CD011594-bbs2-0060" title="KarnerC , CatesCJ . Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008989.pub2] ">Karner 2012</a>). All inhaled beta<sub>2</sub>‐agonists cause bronchodilation through a cascade of reactions by activating beta<sub>2</sub>‐receptors on airway smooth muscle cells, which vary in exact mechanisms of action among different LABAs (<a href="./references#CD011594-bbs2-0061" title="KewKM , MavergamesC , WaltersJA . Long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010177.pub2] ">Kew 2013</a>). Formoterol is a rapidly acting highly selective LABA with minimal affinity for beta<sub>1</sub>‐ and alpha‐adrenergic receptors that causes bronchial relaxation by progressively leaking out from a cell membrane depot to interact with the active site of the beta<sub>2</sub>‐receptor (<a href="./references#CD011594-bbs2-0032" title="BergerWE , NadelJA . Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2008;102:173‐88. ">Berger 2008</a>; <a href="./references#CD011594-bbs2-0058" title="JohnsonM . The beta‐adrenoceptor. American Journal of Respiratory and Critical Care Medicine1998;158:S146‐53. ">Johnson 1998</a>). Salmeterol has a slower onset of action than formoterol, whereby the side chain of salmeterol binds with the beta<sub>2</sub>‐adrenoceptor, but the head continually engages and disengages the active site of the receptor (<a href="./references#CD011594-bbs2-0058" title="JohnsonM . The beta‐adrenoceptor. American Journal of Respiratory and Critical Care Medicine1998;158:S146‐53. ">Johnson 1998</a>; <a href="./references#CD011594-bbs2-0060" title="KarnerC , CatesCJ . Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008989.pub2] ">Karner 2012</a>). Indacaterol has a very quick onset of action of less than five minutes (<a href="./references#CD011594-bbs2-0098" title="ZafarMA , DroegeC , FoertschM , PanosRJ . Update on ultra‐long‐acting beta agonists in chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs2014;23(12):1687‐701. [PUBMED: 25139313] ">Zafar 2014</a>), and its affinity to lipid domains within the membrane is greater than that of salmeterol, resulting in its longer duration of action (<a href="./references#CD011594-bbs2-0031" title="BeierJ , BeehKM . Long‐acting beta‐adrenoceptor agonists in the management of COPD: focus on indacaterol. International Journal of Chronic Obstructive Pulmonary Disease2011;6:237‐43. ">Beier 2011</a>; <a href="./references#CD011594-bbs2-0060" title="KarnerC , CatesCJ . Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008989.pub2] ">Karner 2012</a>). One short‐term unblinded exploratory study found that indacaterol produced significantly greater improvement in inspiratory capacity (<a href="./references#CD011594-bbs2-0030" title="BeierJ , BeehKM , BrookmanL , PeacheyG , HmissiA , PascoeS . Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulmonary Pharmacology and Therapeutics2009;22(6):492‐6. [PUBMED: 19465142] ">Beier 2009</a>). </p> <p>Current guidelines advocate LABAs as first‐line therapy for people with stable COPD, as they reduce exacerbations including those requiring hospitalisations, while improving quality of life and lung function (<a href="./references#CD011594-bbs2-0061" title="KewKM , MavergamesC , WaltersJA . Long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010177.pub2] ">Kew 2013</a>). Addition of regular ICS therapy is recommended only for people with frequent exacerbations (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>; <a href="./references#CD011594-bbs2-0087" title="SpencerS , KarnerC , CatesCJ , EvansDJ . Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD007033.pub3] ">Spencer 2011</a>). Combined therapy of LABA/ICS in one inhaler is associated with a reduction in exacerbations compared with placebo, LABA alone or ICS alone; however, it increases the risk of pneumonia (<a href="./references#CD011594-bbs2-0071" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>; <a href="./references#CD011594-bbs2-0072" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4] ">Nannini 2013a</a>; <a href="./references#CD011594-bbs2-0073" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013b</a>). LABAs have similar efficacy compared with tiotropium for symptom improvement (<a href="./references#CD011594-bbs2-0024" title="AppletonS , JonesT , PooleP , LassersonTJ , AdamsR , SmithB , et al. Ipratropium bromide versus long‐acting beta‐2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD006101] ">Appleton 2006</a>; <a href="./references#CD011594-bbs2-0040" title="ChongJ , KarnerC , PooleP . Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2] ">Chong 2012</a>). </p> <p>Reported adverse effects of LABAs include cardiac events such as arrhythmias, heart failure and acute coronary syndrome; tremors; cough; dry mouth and headache (<a href="./references#CD011594-bbs2-0032" title="BergerWE , NadelJA . Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2008;102:173‐88. ">Berger 2008</a>; <a href="./references#CD011594-bbs2-0053" title="GershonA , CroxfordR , CalzavaraA , ToT , StanbrookMB , UpshurR , et al. Cardiovascular safety of inhaled long‐acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Internal Medicine2013;173(13):1175‐84. ">Gershon 2013</a>), as well as possibly increased risk of cardiovascular death, especially among people with asthma (<a href="./references#CD011594-bbs2-0056" title="HananiaNA . Evaluating the safety of COPD medications: an evidence‐based review. Chest2013;144(4):1357‐67. [PUBMED: 24081347] ">Hanania 2013</a>). However, there is no strong evidence indicating significant differences in mortality or cardiovascular complications between salmeterol or formoterol and placebo in people with COPD (<a href="./references#CD011594-bbs2-0051" title="FergusonGT , Funck‐BrentanoC , FischerT , DarkenP , ReisnerC . Cardiovascular safety of salmeterol in COPD. Chest2003;123(6):1817‐24. ">Ferguson 2003</a>; <a href="./references#CD011594-bbs2-0084" title="RodrigoGJ , NanniniLJ , Rodríguez‐RoisinR . Safety of long acting beta‐agonists in stable COPD: a systematic review. Chest2008;133(5):1079‐87. ">Rodrigo 2008</a>). </p> </section> </section> <section id="CD011594-sec-0028"> <h3 class="title" id="CD011594-sec-0028">How the intervention might work</h3> <p>LABAs and aclidinium result in bronchial smooth muscle relaxation through two different pathways: sympathetic (LABA) and parasympathetic (aclidinium) systems. It is postulated that the activity of the sympathetic system is more prominent in the daytime, whereas the parasympathetic system plays a more important role during the night (<a href="./references#CD011594-bbs2-0037" title="CazzolaM , MolimardM . The scientific rationale for combining long‐acting beta2‐agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics2010;23(4):257‐67. [PUBMED: 20381630] ">Cazzola 2010</a>). A combination of these two medications has the potential to maximise bronchodilation and overcome interpatient and intrapatient variability of bronchomotor tone associated with COPD (<a href="./references#CD011594-bbs2-0037" title="CazzolaM , MolimardM . The scientific rationale for combining long‐acting beta2‐agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics2010;23(4):257‐67. [PUBMED: 20381630] ">Cazzola 2010</a>; <a href="./references#CD011594-bbs2-0044" title="deMiguel‐DiezJ , Jimenez‐GarciaR . Considerations for new dual‐acting bronchodilator treatments for chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs2014; Vol. 23, issue 4:453‐6. [PUBMED: 24392807] ">de Miguel‐Diez 2014</a>; <a href="./references#CD011594-bbs2-0091" title="TashkinDP , FergusonGT . Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory Research2013;14:49. ">Tashkin 2013</a>). Cross‐activity of acetylcholine on the sympathetic system and of adrenergic catecholamines on the parasympathetic system has been reported in preclinical models (<a href="./references#CD011594-bbs2-0066" title="MateraMG , RoglianiP , CazzolaM . Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2014;15(7):961‐77. ">Matera 2014</a>). Acetylcholine‐mediated bronchoconstriction is known to occur primarily via muscarinic receptors of the M3 subtype and is also regulated by prejunctional beta<sub>2</sub>‐adrenoceptors (<a href="./references#CD011594-bbs2-0091" title="TashkinDP , FergusonGT . Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory Research2013;14:49. ">Tashkin 2013</a>). Similarly, a beta‐receptor‐mediated increase in cyclic adenosine monophosphate (cAMP) causing bronchial smooth muscle relaxation is also affected by M2 receptors that functionally oppose by coupling with adenylate cyclase via an inhibitory G protein (<a href="./references#CD011594-bbs2-0066" title="MateraMG , RoglianiP , CazzolaM . Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2014;15(7):961‐77. ">Matera 2014</a>). </p> <p>When LABA/LAMA combined therapy is used, bronchodilation is attained both directly and indirectly. Combining a LABA with aclidinium amplifies the action of aclidinium via modulation of cholinergic neurotransmission by prejunctional beta<sub>2</sub>‐adrenoceptors, in addition to its direct stimulation of smooth muscle beta<sub>2</sub>‐adrenoceptors (<a href="./references#CD011594-bbs2-0038" title="CazzolaM , RoglianiP , MateraMG . Aclidinium bromide/formoterol fumarate fixed‐dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2013;14(6):775‐81. [PUBMED: 23472632] ">Cazzola 2013</a>; <a href="./references#CD011594-bbs2-0094" title="van derMolenT , CazzolaM . Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient‐centred outcomes. Primary Care Respiratory Journal2012;21(1):101‐8. [PUBMED: 22222945] ">van der Molen 2012</a>). Likewise, aclidinium augments beta<sub>2</sub>‐agonist‐stimulated bronchial relaxation by decreasing the bronchoconstrictor effects of acetylcholine (<a href="./references#CD011594-bbs2-0091" title="TashkinDP , FergusonGT . Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory Research2013;14:49. ">Tashkin 2013</a>). Thus, combined aclidinium bromide and LABA is expected to produce more effective bronchodilation than is produced by the individual components alone. </p> </section> <section id="CD011594-sec-0029"> <h3 class="title" id="CD011594-sec-0029">Why it is important to do this review</h3> <p><a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a> suggests the use of LAMA/LABA dual therapy as a treatment alternative for people in GOLD groups B (high symptoms/low risk), C (low symptoms/high risk) and D (high symptoms/high risk). Data from trials on LABA/LAMA combination therapies using a well‐established LAMA, tiotropium, demonstrated greater improvement in patient‐centred outcomes such as dyspnoea, symptoms, rescue medication use and HRQoL than is seen with individual drugs alone (<a href="./references#CD011594-bbs2-0094" title="van derMolenT , CazzolaM . Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient‐centred outcomes. Primary Care Respiratory Journal2012;21(1):101‐8. [PUBMED: 22222945] ">van der Molen 2012</a>). One Cochrane Review reported a slight clinically insignificant improvement in HRQoL with combined LABA and tiotropium compared with tiotropium alone in people with moderate‐to‐severe COPD (<a href="./references#CD011594-bbs2-0060" title="KarnerC , CatesCJ . Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008989.pub2] ">Karner 2012</a>). </p> <p>Aclidinium was approved in 2012 for use in people with moderate‐to‐severe COPD; a considerable number of randomised controlled trials (RCTs) have looked at the benefits and risks of combined aclidinium bromide and LABA compared with placebo or individual inhaled therapies. However, for patients or for clinicians facing patients, the question of how effective and safe this combination is remains unanswered, thus we aimed to fill this gap in evidence by conducting this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011594-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011594-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011594-sec-0145">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011594-sec-0030"></div> <p>To assess the efficacy and safety of combined aclidinium bromide and long‐acting beta<sub>2</sub>‐agonists in stable COPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011594-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011594-sec-0031">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011594-sec-0146">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011594-sec-0031"></div> <section id="CD011594-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011594-sec-0033"> <h4 class="title">Types of studies</h4> <p>We included RCTs of parallel‐group design. We included both open‐label and blinded trials. We excluded cross‐over and cluster‐randomised trials. </p> </section> <section id="CD011594-sec-0034"> <h4 class="title">Types of participants</h4> <p>We included adults over 18 years of age with a diagnosis of COPD according to the criteria of GOLD (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>), the American Thoracic Society (ATS), the European Respiratory Society (ERS) (<a href="./references#CD011594-bbs2-0026" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179‐91. ">ATS/ERS 2011</a>), the Thoracic Society of Australia and New Zealand (TSANZ) (<a href="./references#CD011594-bbs2-0092" title="YangIA , BrownJL , GeorgeJ , JenkinsS , McDonaldCF , McDonaldV , et al. The COPD‐X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2018. Version 2.53, March 2018. www.copdx.org.au/ (accessed 10 July 2018). ">TSANZ 2018</a>), the UK National Institute for Health and Care Excellence (<a href="./references#CD011594-bbs2-0076" title="National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). www.nice.org.uk/guidance/cg101/resources/guidance‐chronic‐obstructive‐pulmonary‐disease‐pdf (accessed 30 October 2014). ">NICE 2010</a>), or the World Health Organization (<a href="./references#CD011594-bbs2-0096" title="Diagnosis of COPD. http://www.who.int/respiratory/copd/diagnosis/en/. ">WHO</a>). Participants had evidence of airway obstruction (postbronchodilator forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC) ratio less than 70%) with symptoms of dyspnoea, chronic cough or sputum production with or without a history of smoking. We excluded studies that enrolled participants with bronchial asthma, bronchiectasis, cystic fibrosis or other chronic lung diseases. </p> </section> <section id="CD011594-sec-0035"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing aclidinium bromide/LABA versus placebo, aclidinium bromide, LABA or LAMA. LABA and LAMA must have been part of the randomly assigned treatments in the included studies. The minimum duration of trials was four weeks. We planned to study the following comparisons. </p> <p> <ul id="CD011594-list-0001"> <li> <p>Aclidinium bromide/LABA free combination in separate inhalers:</p> <ul id="CD011594-list-0002"> <li> <p>versus aclidinium bromide;</p> </li> <li> <p>versus the same LABA;</p> </li> <li> <p>versus LAMA; or</p> </li> <li> <p>versus placebo.</p> </li> </ul> </li> <li> <p>Aclidinium bromide/LABA fixed‐dose combination (FDC) in one inhaler:</p> <ul id="CD011594-list-0003"> <li> <p>versus aclidinium bromide;</p> </li> <li> <p>versus the same LABA;</p> </li> <li> <p>versus LAMA; or</p> </li> <li> <p>versus placebo.</p> </li> </ul> </li> </ul> </p> <p>We included the following cointerventions provided they are not part of the randomised treatment: salbutamol or albuterol as rescue medication, oral sustained‐release theophylline, ICSs or systemic corticosteroids (oral or parenteral) at stable doses and oxygen therapy of less than 15 hours/day. </p> </section> <section id="CD011594-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD011594-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011594-list-0004"> <li> <p>Exacerbations requiring a short course of an oral steroid or antibiotic, or both.</p> </li> <li> <p>Quality of life as measured by a validated scale, St George's Respiratory Questionnaire (SGRQ) or the Chronic Respiratory Disease Questionnaire (CRQ). </p> </li> <li> <p>Non‐fatal serious adverse events (SAE) such as any adverse event that is life‐threatening or places the participant at immediate risk of death; requires in‐patient hospitalisation or prolongs hospitalisation; causes persistent or significant disability/incapacity (i.e. a substantial disruption in an individual’s ability to conduct normal life functions); results in congenital anomalies or birth defects; or other medically important conditions which investigators judge to represent significant hazards </p> </li> </ul> </p> </section> <section id="CD011594-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011594-list-0005"> <li> <p>Mortality (all‐cause and respiratory).</p> </li> <li> <p>Hospital admissions due to exacerbations.</p> </li> <li> <p>Improvement in symptoms as measured by the Transitional Dyspnoea Index (TDI).</p> </li> <li> <p>Change in lung function.</p> </li> <li> <p>Adverse events not including SAEs.</p> </li> </ul> </p> <p>Reporting in the trial of one of more of the outcomes listed here was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD011594-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011594-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Airways Trials Register up to 12 October 2018 with no restrictions on language or type of publication. The Cochrane Airways Trials Register is maintained by the information specialist for Cochrane Airways and contains studies identified from the following sources: </p> <p> <ul id="CD011594-list-0006"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies (CRS); </p> </li> <li> <p>weekly searches of MEDLINE Ovid;</p> </li> <li> <p>weekly searches of Embase Ovid;</p> </li> <li> <p>monthly searches of PsycINFO Ovid;</p> </li> <li> <p>monthly searches of CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature);</p> </li> <li> <p>monthly searches of AMED EBSCO (Allied and Complementary Medicine);</p> </li> <li> <p>handsearches of the proceedings of major respiratory conferences.</p> </li> </ul> </p> <p>Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings are in <a href="./appendices#CD011594-sec-0119">Appendix 1</a>. See <a href="./appendices#CD011594-sec-0125">Appendix 2</a> for search terms used to identify studies for this review. </p> <p>We also conducted a search of www.ClinicalTrials.gov (<a href="./appendices#CD011594-sec-0126">Appendix 3</a>) and the WHO trials portal (<a href="./references#CD011594-bbs2-0097" title="World Health Organization. International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed 30 October 2014). ">WHO ICTRP</a>) up to 12 October 2018. </p> </section> <section id="CD011594-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We searched relevant manufacturers' websites (<a href="./references#CD011594-bbs2-0052" title="ForestPharmaceuticals , Inc . Research and Development. www.frx.com/Research (accessed 26 January 2015). ">Forest Pharmaceuticals</a>, <a href="./references#CD011594-bbs2-0023" title="Almirall . Clinical trials registry and results. www.almirall.com/en/about‐almirall/research‐and‐development/clinical‐trials (accessed 26 January 2015). ">Almirall</a>, and <a href="./references#CD011594-bbs2-0025" title="AstraZeneca . AstraZeneca Clinical Trials. astrazenecagrouptrials.pharmacm.com/ST/Submission/Search (accessed prior to 19 July 2018). ">AstraZeneca</a>) and the US FDA website (<a href="./references#CD011594-bbs2-0046" title="FDA . United States Food and Drug Administration. www.fda.gov/ (accessed 26 January 2015). ">FDA</a>) for trial information. We also searched for errata or retractions from included studies published as full‐text articles on <a href="./references#CD011594-bbs2-0078" title="PubMed . US National Library of Medicine, National Institutes of Health database. www.ncbi.nlm.nih.gov/pubmed (accessed 30 October 2014). ">PubMed</a> and reported within the review the date this was done. We planned to translate trials published in a language other than English. The date of the last search was 12 October 2018. </p> </section> </section> <section id="CD011594-sec-0042"> <h3 class="title" id="CD011594-sec-0042">Data collection and analysis</h3> <section id="CD011594-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HN and KTM) independently screened titles and abstracts for inclusion of all potential studies identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve.' Two review authors (SM and KTM) independently screened the full‐text articles, identified studies for inclusion, and identified and recorded reasons for exclusion of ineligible studies. We resolved disagreements through discussion, or, if required, we consulted a third review author (ZS). We identified and excluded duplicates and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and a <a href="./references#CD011594-sec-0135" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD011594-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form that was piloted on at least one study in the review to document study characteristics and outcome data. One review author (SM) extracted the following characteristics from included studies. </p> <p> <ul id="CD011594-list-0007"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and locations, study setting, withdrawals and date of study. </p> </li> <li> <p>Participants: number, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected and time points reported.</p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (HN and KTM) independently extracted outcome data from included studies. We noted in the <a href="./references#CD011594-sec-0134" title="">Characteristics of included studies</a> table if outcome data were not reported in a usable way. We resolved disagreements by consensus or by consultation with a third review author (KNV). One review author (HN) transferred data into Review Manager 5 (<a href="./references#CD011594-bbs2-0082" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review versus those provided in the study reports. A second review author (KTM) spot‐checked study characteristics for accuracy against those provided in the trial report. </p> </section> <section id="CD011594-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HN and SM) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011594-bbs2-0057" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved disagreements by discussion or by consultation with another review author (ZS). We assessed risk of bias according to the following domains. </p> <p> <ul id="CD011594-list-0008"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for all‐cause mortality may be very different than for a participant‐reported pain scale). When information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account risk of bias for the studies that contributed to that outcome. </p> <section id="CD011594-sec-0046"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported deviations from it in the <a href="#CD011594-sec-0132">Differences between protocol and review</a> section of the systematic review. </p> </section> </section> <section id="CD011594-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as odds ratios (OR), and continuous data as mean differences (MD) if studies used the same measurement scale or standardised mean differences (SMD) if studies used different scale measurements, with 95% confidence intervals (CI). We entered data presented as a scale with a consistent direction of effect. We applied Peto OR, with 95% CI for rare events. </p> <p>We undertook meta‐analyses only when this was meaningful (i.e. if treatments, participants and the underlying clinical question were similar enough for pooling to make sense). We narratively described skewed data reported as medians and interquartile ranges. When multiple trial arms were reported in a single trial, we included only the relevant arms in the analysis and reported the other treatment arms in the <a href="./references#CD011594-sec-0134" title="">Characteristics of included studies</a> table. When two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we halved the control group to avoid double‐counting. </p> </section> <section id="CD011594-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed the number of participants instead of the number of events for outcomes that may have occurred more than once, such as exacerbations, hospital admissions and adverse events. For exacerbation rates, we planned to analyse the data as rate ratios, transformed them into log rate ratios and combined them across studies using the generic inverse variance method. </p> <p>To prevent unit of analysis error In studies with multiple intervention arms, for dichotomous data, we divided up both the number of participants and the number of events according to the number of interventions in the study. For continuous data, we only divided the total number of participants and the means and standard deviations remained unchanged. If we needed to combine groups, we summed both sample sizes and the numbers of people with events for dichotomous outcomes. For continuous outcomes, we used the formula described in Table 7.7a in Section 7.7.3.8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to combine means and standard deviations (<a href="./references#CD011594-bbs2-0057" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD011594-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was identified as an abstract only). When this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by performing a sensitivity analysis. </p> </section> <section id="CD011594-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (I² greater than 50%), we reported this and explored possible causes by performing prespecified subgroup analysis. </p> </section> <section id="CD011594-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had been able to pool more than 10 trials, we planned to create and examine a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD011594-sec-0052"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model and performed a sensitivity analysis using a fixed‐effect model. We applied a fixed‐effect model if the I² statistic showed homogeneous results, and a random‐effects model for data synthesis when there was significant heterogeneity (I² greater than 50%) that could not be explained by subgroup analyses. </p> <p>We combined dichotomous outcome variables using a Mantel‐Haenszel OR with 95% CIs. For continuous outcomes, we analysed data as MDs with 95% CIs. We calculated the number needed to treat for an additional beneficial outcome (NNTB) from the pooled OR and assumed control risk using the formula described in Section 12.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011594-bbs2-0057" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <section id="CD011594-sec-0053"> <h5 class="title">'Summary of findings' tables</h5> <p>We created 'Summary of findings' tables using the following outcomes.</p> <p> <ul id="CD011594-list-0009"> <li> <p>Exacerbations requiring a short course of an oral steroid or antibiotic, or both.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Non‐fatal SAEs.</p> </li> <li> <p>Hospital admissions due to exacerbations.</p> </li> <li> <p>Improvement in symptoms.</p> </li> <li> <p>Change in lung function (trough FEV<sub>1</sub>). </p> </li> <li> <p>Adverse events not including SAEs.</p> </li> </ul> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta‐analyses for prespecified outcomes. We applied methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011594-bbs2-0057" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) using GRADEpro software. We justified all decisions to downgrade or upgrade the certainty of studies by using footnotes, and we made comments to aid readers' understanding of the review when necessary. </p> </section> </section> <section id="CD011594-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ul id="CD011594-list-0010"> <li> <p>Dose of LABAs (e.g. formoterol 6 µg, formoterol 12 µg, formoterol 18 µg).</p> </li> <li> <p>Different LABAs (e.g. formoterol, salmeterol, indacaterol).</p> </li> <li> <p>Concurrent use of ICS (dichotomised as yes/no).</p> </li> </ul> </p> <p>We planned to use the following outcomes in subgroup analyses.</p> <p> <ul id="CD011594-list-0011"> <li> <p>Exacerbations requiring a short course of an oral steroid or antibiotic, or both.</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Non‐fatal SAEs.</p> </li> <li> <p>Improvement in symptoms.</p> </li> </ul> </p> <p>We used the formal test for subgroup interactions provided in Review Manager 5 (<a href="./references#CD011594-bbs2-0082" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD011594-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses.</p> <p> <ul id="CD011594-list-0012"> <li> <p>Repeating the meta‐analysis after exclusion of trials with high risk of bias or unclear methodological data. </p> </li> <li> <p>Performing the meta‐analysis by using both a random‐effects model and a fixed‐effect model. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011594-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011594-sec-0056"></div> <section id="CD011594-sec-0057"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD011594-sec-0134" title="">Characteristics of included studies</a>; <a href="./references#CD011594-sec-0135" title="">Characteristics of excluded studies</a>; <a href="./references#CD011594-sec-0136" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD011594-sec-0137" title="">Characteristics of ongoing studies</a> tables for detailed description. </p> <section id="CD011594-sec-0058"> <h4 class="title">Results of the search</h4> <p>We conducted the initial search of the Cochrane Airways Group Specialised Register of trials (CAGR) on 11 March 2015 and the search of other sources (www.clinicaltrials.gov; <a href="./references#CD011594-bbs2-0097" title="World Health Organization. International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed 30 October 2014). ">WHO ICTRP</a>; <a href="./references#CD011594-bbs2-0023" title="Almirall . Clinical trials registry and results. www.almirall.com/en/about‐almirall/research‐and‐development/clinical‐trials (accessed 26 January 2015). ">Almirall</a>) on 13 March 2015, 29 March 2015 and 1 April 2015, respectively with no restriction on language. Updated search was performed in August 2017 for CAGR and September 2017 for other sources. Since the aclidinium trials had been taken over by <a href="./references#CD011594-bbs2-0025" title="AstraZeneca . AstraZeneca Clinical Trials. astrazenecagrouptrials.pharmacm.com/ST/Submission/Search (accessed prior to 19 July 2018). ">AstraZeneca</a>, we searched their website (<a href="./references#CD011594-bbs2-0025" title="AstraZeneca . AstraZeneca Clinical Trials. astrazenecagrouptrials.pharmacm.com/ST/Submission/Search (accessed prior to 19 July 2018). ">AstraZeneca</a>) in 2017. A prepublication literature search update was done on 12 October 2018. </p> <p>We identified 384 (132 plus 178 plus 74) records from the CAGR, 104 (89 plus 15) from WHO ICTRP, 43 (21 plus 22) from www.clinicaltrials.gov, 25 (two plus 23) from <a href="./references#CD011594-bbs2-0023" title="Almirall . Clinical trials registry and results. www.almirall.com/en/about‐almirall/research‐and‐development/clinical‐trials (accessed 26 January 2015). ">Almirall</a> and <a href="./references#CD011594-bbs2-0025" title="AstraZeneca . AstraZeneca Clinical Trials. astrazenecagrouptrials.pharmacm.com/ST/Submission/Search (accessed prior to 19 July 2018). ">AstraZeneca</a> clinical trial registry, and one from a reference list. After removal of duplicates, we screened the titles and abstracts of 387 records for eligibility and excluded 323 reports as obviously irrelevant based on title and abstract. We thoroughly studied the remaining 64 references for further assessment, retrieving full‐text articles where applicable. From our search, we excluded 23 references for 13 studies with complete agreement between the review authors. Details of studies that failed to meet the inclusion criteria were recorded in the <a href="./references#CD011594-sec-0135" title="">Characteristics of excluded studies</a> table. We identified seven studies reported in 38 references that were eligible for inclusion. There was one ongoing study with estimated completion date in 2018 (<a href="./references#CD011594-bbs2-0022" title="NCT03022097 . Study to patients with stable COPD to assess the efficacy and safety of aclidinium bromide/formoterol fumarate (DUAKLIR). clinicaltrials.gov/show/NCT03022097 Date first received: 16 January 2017. ">AVANT</a>). We identified one study with two references that had completed recently with no published results for further classification (<a href="./references#CD011594-bbs2-0021" title="EUCTR2015‐005444‐33‐GB . A 24 week treatment, multicentre, randomised, double blinded, double dummy, parallel‐group, clinical trial evaluating the efficacy and safety of aclidinium bromide 400 µg/formoterol fumarate 12 µg fixed‐dose combination BID compared with each monotherapy (aclidinium bromide 400 µg BID and formoterol fumarate 12 µg BID) and tiotropium 18 µg QD when administered to patients with stable chronic obstructive pulmonary disease – AMPLIFY. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015‐005444‐33‐GB Date first received: 13 April 2016. NCT02796677 . AMPLIFY – D6571C00001 Duaklir USA phase III study. clinicaltrials.gov/show/NCT027966772016; Vol. Date first received: 13 June 2016. ">AMPLIFY</a>). For details of the search results, see <a href="#CD011594-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011594-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011594-sec-0059"> <h4 class="title">Included studies</h4> <p>See <a href="#CD011594-tbl-0004">Table 1</a> for an overview of the included studies. </p> <div class="table" id="CD011594-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1729</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg twice daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 400 μg twice daily</p> <p>Inhaled formoterol 12 μg twice daily</p> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1692</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg twice daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 400 μg twice daily</p> <p>Inhaled formoterol 12 μg twice daily</p> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a> </p> <p>(extension study of AUGMENT COPD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>921</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg twice daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 400 μg twice daily</p> <p>Inhaled formoterol 12 μg twice daily</p> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled formoterol 12 μg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 200/12 μg once daily in the morning and placebo once daily in the evening </p> <p>Inhaled FDC aclidinium/formoterol 200/12 μg once daily in the morning and formoterol 12 μg once daily in the evening </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled formoterol 12 μg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>566</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg once daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg once daily</p> <p>Inhaled FDC aclidinium/formoterol 400/18 μg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 200 μg once daily</p> <p>Inhaled formoterol 12 μg once daily</p> <p>Inhaled placebo once daily</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FDC: fixed‐dose combination.</p> </div> </div> <section id="CD011594-sec-0060"> <h5 class="title">Study design, duration and setting</h5> <p>All the included trials were double‐blind, randomised, parallel‐group studies, assessing combined aclidinium bromide/formoterol as FDC in one inhaler. Four trials were active comparator (aclidinium/formoterol) and placebo controlled (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), two trials compared FDC with formoterol (<a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>), and one trial assessed FDC versus placebo (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>). Four trials were phase three studies (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>), two were phase two studies (<a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), and one was a phase four study (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>). <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a> was the 28‐week extension study of <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>, in which the participants who agreed for this extension study were kept on the same treatment and placebo arms as in the primary study. </p> <p>The total duration of studies ranged from four to 52 weeks, with a mean of 20.6 weeks. Four of the included trials were of long duration with two studies of 24 weeks (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>), one study of 28 weeks (<a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>), and one study of 52 weeks (<a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). The remaining studies were of four weeks' (<a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>) and eight weeks' duration (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>). </p> <p>Most of the studies were based in the US (<a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>), Canada (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>), Europe (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), and Australia and New Zealand (<a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). Other study locations were South Africa (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>), and Asian countries of South Korea (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>), and India, Malaysia and Taiwan (<a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). </p> </section> <section id="CD011594-sec-0061"> <h5 class="title">Participants</h5> <p>The seven eligible studies randomised 5921 participants. <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> was the largest trial with 1729 participants, while <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a> had the least number of participants with only 156. The number of participants of other studies ranged from 267 to 1692. </p> <p>The participants men and women aged 40 years or older, who were current or former cigarette smokers with a smoking history of 10 or more pack‐years and diagnosed with stable moderate‐to‐severe airway obstruction according to GOLD criteria (postbronchodilator FEV<sub>1</sub>/FVC ratio less than 70% and FEV<sub>1</sub> 30% or greater but less than 80% of predicted normal value). The mean age of participants ranged from 60.7 to 64.7 years, with more men (3555) than women (2366). More than 90% of the participants were white in three studies (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>); the other studies did not specify the race of the participants. The percentage of current smokers ranged from 43.9% to 63.4%, with mean smoking of 46.4 pack‐years to 61.3 pack‐years. Participants had moderate‐to‐severe COPD according to GOLD criteria though <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a> did not mention the specific criteria used for severity assessment. The participants' mean postbronchodilator FEV<sub>1</sub> was between 50.5% and 61% of predicted normal with their baseline mean FEV<sub>1</sub> ranging from 1.23 L to 1.43 L. </p> </section> <section id="CD011594-sec-0062"> <h5 class="title">Interventions</h5> <p>All included trials assessed the efficacy and safety of combined aclidinium bromide/formoterol as FDC in one inhaler and we found no trials assessing the combination of aclidinium with other LABAs or in separate inhalers. The participants underwent a two‐ to three‐week run‐in period for disease stability and washout of disallowed medications in three trials (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>), while the duration of run‐in and screening period was 11 to 17 days in <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>. Six trials had a treatment arm of FDC of aclidinium 400 μg plus formoterol 12 μg (FDC 400/12 μg) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>), and three studies assessed aclidinium/formoterol FDC 400/6 μg (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>). Dose of aclidinium in FDC investigated in the initial phases of clinical development was 200 μg, which was later proved to be suboptimal (<a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). </p> <p>Three main studies assessed two doses of FDC (400/6 μg, 400/12 μg) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>), and one study assessed three doses of FDC (200/6 μg, 200/12 μg, 200/18 μg) (<a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), in comparison to aclidinium monotherapy, formoterol monotherapy and placebo. <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a> was the extension of <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> in which consented participants who completed the primary study remained on the same intervention arm in a double‐blind method for another 28 weeks. Two studies compared FDC 400/12 μg to formoterol (<a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>), and one study compared FDC 400/12 μg versus placebo (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>). </p> <p>Three trials delivered FDC, aclidinium monotherapy, formoterol monotherapy and placebo twice daily via Genuair inhaler (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>), and one trial delivered them once daily (<a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). One trial administered FDC 400/12 μg and formoterol 12 μg twice daily (<a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). One trial studied twice‐daily FDC 400/12 μg versus placebo (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>). One trial allocated participants into three arms, both intervention arms received FDC 200/12 μg once daily in the morning with placebo in the evening in one arm and formoterol in the evening in the other arm; along with the comparator arm of formoterol 12 μg twice daily, all delivered via Genuair inhaler (<a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>). </p> </section> <section id="CD011594-sec-0063"> <h5 class="title">Concomitant medications</h5> <p>Five studies with full‐text publications stated that participants were permitted to continue ICSs, oral or parenteral corticosteroids at doses equivalent to prednisolone of 10 mg/day or less or 20 mg every other day, oxygen therapy for less than 15 hours per day, provided treatment was stable for at least four weeks prescreening as well as the use of albuterol/salbutamol as rescue medication (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). Four trials permitted oral sustained‐release methylxanthines (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>), though one trial prohibited it (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>). Four trials did not permit any bronchodilator treatment other than the investigative and rescue medications (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). The remaining two studies were in abstract form and there was no detailed description with respect to concomitant medications (<a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). </p> </section> <section id="CD011594-sec-0064"> <h5 class="title">Outcomes</h5> <p>The primary outcomes of the included studies and our review's primary outcomes were not the same since most of the individual trials assessed lung function as the primary outcome. Change from baseline in trough FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>) and one‐hour postmorning dose FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>) were the primary outcomes in individual trials which were analysed as secondary outcomes in our review. Other lung function parameters such as change from baseline in trough functional residual capacity (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>), normalised FEV<sub>1</sub> area under the curve, peak FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>) were also studied as primary outcomes whereas lung function tests with no further specification were the secondary outcomes for <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>. </p> <p>Quality of life measured by the SGRQ total score, one of the primary outcomes of our review, was studied in the two pivotal trials as secondary outcome (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>), and we analysed as both change from the baseline and percentage of participants with at least four unit decrease (minimal clinically important difference). </p> <p>The safety data on adverse events not including SAEs, non‐fatal SAEs and mortality of all cause were studied as primary (<a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>) and secondary outcomes (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), and well reported in the full‐text publications as well as in the European Public Assessment Report (EPAR). Though it is unlikely that a 24‐week study is long enough to demonstrate a clinically meaningful effect on exacerbations, necessary information regarding the number of participants with hospital admissions due to exacerbations and exacerbations who required a short course of oral steroids or antibiotics, or both were provided by the study sponsors. Improvement in symptoms measured in TDI score was studied as secondary outcome in <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> and <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>, reported in the respective publications. Data in the format required for the meta‐analysis of some of the outcomes, especially SGRQ and TDI score, were kindly provided on request. </p> </section> <section id="CD011594-sec-0065"> <h5 class="title">Funding</h5> <p>All studies were sponsored by Almirall (SA, Barcelona, Spain) and Forest Laboratories, Inc (New York, USA) or Menarini Group through its affiliate Berlin‐Chemie and AstraZeneca. </p> </section> </section> <section id="CD011594-sec-0066"> <h4 class="title">Excluded studies</h4> <p>Thirteen trials did not meet our eligibility criteria, seven were of cross‐over study design, four studied aclidinium bromide/formoterol fumarate combination with no comparator arm according to our review, one assessed the preference between Genuair and HandiHaler inhalers, and one was withdrawn prior to enrolment (<a href="./references#CD011594-bbs2-0009" title="NCT03181880 . To evaluate effectiveness of aclidinium bromide/formoterol fumarate dihydrate in chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT03181880 Date first received: 9 June 2017. ">ASTUTE</a>) (see <a href="./references#CD011594-sec-0135" title="">Characteristics of excluded studies</a> table for details). </p> </section> </section> <section id="CD011594-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>Assessments of risk of bias in included studies are presented in detail in the <a href="./references#CD011594-sec-0134" title="">Characteristics of included studies</a> table and <a href="#CD011594-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD011594-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011594-sec-0068"> <h4 class="title">Allocation</h4> <p>The published article on <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> mentioned allocation using a centralised interactive voice response system with stratification by smoking status (smoker or ex‐smoker) in detail. The study concealed treatment identity with identical packaging/appearance and no odour or colour. <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> and its extension study <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a> generated randomisation codes by statistical programming and implemented by an interactive web response system. <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a> used a similar interactive web response system provided by Premier Research Group Limited (East Hartford, CT, USA) to assign patient identification numbers. Thus, the risk of bias for selection and allocation was low for these studies. However, the remaining trials were at unclear risk as they did not mention random sequence generation and allocation details (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). </p> </section> <section id="CD011594-sec-0069"> <h4 class="title">Blinding</h4> <p>All the included trials were double blind where investigators, participants and carers were unaware of the intervention received. Therefore, we judged these studies at low risk of bias. Investigators administered the study drugs in a double‐blind pattern where neither the attending physician nor the participant knew which intervention arm a particular participant was in. Furthermore, the study medications were in identical packaging or of appearance and delivered by a similar inhaler device. All inhalers were identical from an external perspective where the only difference between them was that placebo did not contain active ingredient. The active ingredients had no perceptible taste, appearance, odour or colour that could unmask the blinding. Independent adjudication committee members who were not participating in the study and were blinded to treatment evaluated outcomes. For safety outcomes, blinded independent expert cardiologists not participating in the study performed the assessment of major adverse cardiac events (<a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). </p> </section> <section id="CD011594-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>All included studies reported with reasons the total number of withdrawals for each study arm in full‐text articles (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>) or the study results from the clinicaltrials.gov (<a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). The withdrawal rates were relatively low with similar reasons across the study arms in four trials (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), thus the risk of attrition bias for these studies was low. We assessed the attrition bias for the remaining three studies as unclear because the dropout rates were high even though they were relatively similar among the study arms (<a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). All studies performed efficacy by intention to treat and safety analysis in the safety population, which was defined as all randomised participants who had received at least one dose of study medication. </p> </section> <section id="CD011594-sec-0071"> <h4 class="title">Selective reporting</h4> <p>Both full‐text publications and clinical study synopses described the results of all prespecified outcomes for all included studies, without obvious reporting bias. Moreover, trial result summaries for those started in late 2015 and beyond were available on the AztraZeneca website regardless of the positive or negative effects of the study medication which made reporting bias very unlikely. However, <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> did not report data on the percentage of participants with clinically significant improvement in SGRQ total score of at least four units for FDC compared to formoterol in any of the published texts despite reporting the absolute change of SGRQ score for these arms, thus this study was at unclear risk of reporting bias. </p> </section> <section id="CD011594-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>Almirall funded the initial six trials (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>) and <a href="./references#CD011594-bbs2-0025" title="AstraZeneca . AstraZeneca Clinical Trials. astrazenecagrouptrials.pharmacm.com/ST/Submission/Search (accessed prior to 19 July 2018). ">AstraZeneca</a> sponsored the latest trial (<a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>) following the agreement between Almirall and AztraZeneca on the transition of the Almirall respiratory studies. Study authors disclosed any possible conflicts of interest, both financial and non‐financial, in the published articles, thus we detected no other possible sources of bias. </p> </section> </section> <section id="CD011594-sec-0073"> <h3 class="title" id="CD011594-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD011594-tbl-0001"><b>Summary of findings for the main comparison</b> Fixed‐dose combination aclidinium/formoterol compared to aclidinium alone for chronic obstructive pulmonary disease (COPD)</a>; <a href="./full#CD011594-tbl-0002"><b>Summary of findings 2</b> Fixed‐dose combination aclidinium/formoterol compared to formoterol for chronic obstructive pulmonary disease (COPD)</a>; <a href="./full#CD011594-tbl-0003"><b>Summary of findings 3</b> Fixed‐dose combination aclidinium/formoterol compared to placebo for chronic obstructive pulmonary disease (COPD)</a> </p> <p>We only identified trials on combined aclidinium bromide and formoterol in FDC and included data from all studies except <a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a> for quantitative synthesis (meta‐analysis). We compared FDC of aclidinium bromide/formoterol versus aclidinium, formoterol and placebo. None of the seven studies were designed to enrol people with exacerbation‐prone COPD. None of the included studies required participants to have at least two prior year exacerbations or at least one prior year hospitalisation. Therefore, there were no currently published studies of aclidinium/formoterol specifically designed or powered to look for benefits on COPD exacerbation endpoints for dual therapy versus monotherapy. </p> <section id="CD011594-sec-0074"> <h4 class="title">1. Fixed‐dose combination aclidinium/formoterol versus aclidinium alone</h4> <section id="CD011594-sec-0075"> <h5 class="title">Primary outcomes</h5> <section id="CD011594-sec-0076"> <h6 class="title">Exacerbations requiring a short course of an oral steroid or antibiotic, or both</h6> <p>Analysis of 2156 participants from two trials found no evidence of a difference between FDC aclidinium/formoterol and aclidinium alone for the number of participants experiencing at least one exacerbation requiring a short course of oral steroids or antibiotics, or both over 24 weeks (OR 0.95, 95% CI 0.71 to 1.27; moderate‐certainty evidence; <a href="./references#CD011594-fig-0007" title="">Analysis 1.1</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). Published articles did not report this outcome, however, the sponsors provided the data necessary for this analysis. Subgroup analysis for the FDC doses of formoterol 12 μg (OR 0.91, 95% CI 0.60 to 1.39; 2 trials, 1080 participants) and 6 μg (OR 0.99, 95% CI 0.65 to 1.49; 2 trials, 1076 participants) demonstrated a similar result with no evidence of a difference between the subgroups (test for subgroup differences: P = 0.80). </p> </section> <section id="CD011594-sec-0077"> <h6 class="title">Quality of life</h6> <p>Two trials studied quality of life as change from baseline in SGRQ total score as well as the number of participants who attained a minimal clinically significant reduction of at least four units (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). From the meta‐analysis of 2002 participants, there was no evidence of a difference in change from baseline of mean SGRQ total score with FDC aclidinium/formoterol compared to aclidinium alone (MD –0.92, 95% CI –2.15 to 0.30; <a href="./references#CD011594-fig-0008" title="">Analysis 1.2</a>). There was no evidence of a difference over aclidinium monotherapy for FDC doses using formoterol 12 μg (MD –0.77. 95% CI –2.51 to 0.96; 2 trials, 1004 participants) and 6 μg (MD –1.08, 95% CI –2.81 to 0.65; 2 trials, 998 participants) (test for subgroup differences: P = 0.81). </p> <p>This translated into no evidence of a difference in the number of participants who achieved a minimal clinically important improvement of SGRQ total score reduction of at least four units over 24 weeks between FDC aclidinium/formoterol and aclidinium alone (OR 1.17, 95% CI 0.97 to 1.41; 2 trials, 2002 participants; <a href="./references#CD011594-fig-0009" title="">Analysis 1.3</a>). In absolute terms, 579/1000 participants (95% CI 533/1000 to 624/1000) treated with FDC aclidinium/formoterol reported a clinically important improvement in quality of life while 541/1000 participants taking aclidinium alone experienced the same improvement (moderate‐certainty evidence; <a href="./full#CD011594-tbl-0001">summary of findings Table for the main comparison</a>). Neither of the FDC doses containing formoterol 12 μg (OR 1.12, 95% CI 0.86 to 1.45; 2 trials, 1004 participants) nor 6 μg (OR 1.22, 95% CI 0.93 to 1.59; 2 trials, 998 participants) demonstrated a significant improvement over aclidinium (test for subgroup differences: P = 0.65). </p> </section> <section id="CD011594-sec-0078"> <h6 class="title">Non‐fatal serious adverse events</h6> <p>The pooled analysis of data from three studies revealed no evidence of a difference in non‐fatal SAEs between FDC aclidinium/formoterol and aclidinium alone groups (OR 1.19, 95% CI 0.79 to 1.80; 2473 participants; moderate‐certainty evidence; <a href="./references#CD011594-fig-0010" title="">Analysis 1.4</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). In 1000 participants, 49 (95% CI 33 to 72) in the FDC aclidinium/formoterol group developed non‐fatal SAEs compared to 41 in the aclidinium alone group (<a href="./full#CD011594-tbl-0001">summary of findings Table for the main comparison</a>). Subgroup analysis showed no evidence of a difference between the FDC dose of formoterol 12 μg (OR 1.32, 95% CI 0.74 to 2.36; 3 trials, 1238 participants) and 6 μg (OR 1.07, 95% CI 0.60 to 1.92; 3 trials, 1235 participants) (test for subgroup differences: P = 0.62). </p> </section> </section> <section id="CD011594-sec-0079"> <h5 class="title">Secondary outcomes</h5> <section id="CD011594-sec-0080"> <h6 class="title">Mortality</h6> <p>Three trials reported the total number of deaths. There were no deaths in either FDC aclidinium/formoterol and aclidinium alone arms in <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a> during the four‐week study period (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). The total number of deaths due to all causes was not significantly different between FDC aclidinium/formoterol‐treated and aclidinium‐treated participants (Peto OR 0.66, 95% CI 0.14 to 3.16; 3 trials, 2473 participants; <a href="./references#CD011594-fig-0011" title="">Analysis 1.5</a>). </p> </section> <section id="CD011594-sec-0081"> <h6 class="title">Hospital admissions due to exacerbations</h6> <p>Meta‐analysis of data from two studies demonstrated no evidence of a difference in the number of participants who required at least one hospital admission due to severe exacerbations between FDC aclidinium/formoterol and aclidinium alone (OR 0.62, 95% CI 0.29 to 1.29; 2156 participants; moderate‐certainty evidence; <a href="./references#CD011594-fig-0012" title="">Analysis 1.6</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). Neither FDC with formoterol 12 µg (OR 0.58, 95% CI 0.19 to 1.74; 2 trials, 1080 participants) nor FDC with formoterol 6 µg (OR 0.65, 95% CI 0.24 to 1.75; 2 trials, 1076 participants) were associated with a significant reduction in hospitalisations compared to aclidinium monotherapy (test for subgroup differences: P = 0.88). Among 1000 participants, 11 (95% CI 5 to 23) in the FDC aclidinium/formoterol group and 18 in the aclidinium alone group experienced at least one severe COPD exacerbation necessitating hospital admission (<a href="./full#CD011594-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011594-sec-0082"> <h6 class="title">Improvement in symptoms</h6> <p>Two studies assessed symptomatic improvement in dyspnoea by TDI focal score as the change from baseline in mean value to the end of the study over 24 weeks as well as the number of participants with at least one unit increment which was of minimal clinically important difference (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). Overall, FDC aclidinium/formoterol significantly increased TDI focal score from baseline with an MD of 0.37 units compared to aclidinium (95% CI 0.07 to 0.68; 2013 participants; <a href="./references#CD011594-fig-0013" title="">Analysis 1.7</a>; <a href="#CD011594-fig-0003">Figure 3</a>). Similarly, FDC aclidinium/formoterol was associated with a statistically significant difference in the number of participants with at least one unit improvement in TDI focal score compared to aclidinium alone (OR 1.34, 95% CI 1.11 to 1.62; 2013 participants; <a href="./references#CD011594-fig-0014" title="">Analysis 1.8</a>). In absolute terms, 627/1000 (95% CI 582 to 671) participants receiving FDC aclidinium/formoterol reported a clinically significant symptomatic improvement compared to 557/1000 participants given aclidinium alone, indicating 70 more (25 more to 114 more) participants attained this improvement. Thus, for every 14 participants given FDC aclidinium/formoterol, one more person experienced a clinically important improvement of at least one unit increase in TDI focal score (95% CI 9 to 39, high‐certainty evidence; <a href="./full#CD011594-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD011594-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score." data-id="CD011594-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score. </p> </div> </div> </div> <p>Upon subgroup analyses, both FDC doses containing formoterol 12 µg (MD 0.42, 95% CI –0.01 to 0.85; 2 trials, 1012 participants) and formoterol 6 µg (MD 0.33, 95% CI –0.10 to 0.76; 2 trials, 1001 participants) showed no significant change from baseline TDI focal score (test for subgroup differences: P = 0.76; <a href="./references#CD011594-fig-0013" title="">Analysis 1.7</a>). Likewise, there was no evidence of a difference between FDC containing formoterol 12 µg (OR 1.28, 95% CI 0.98 to 1.67; 2 trials, 1012 participants) and formoterol 6 µg (OR 1.40, 95% CI 1.08 to 1.84; 2 trials, 1001 participants) in the proportion of participants with clinically important symptomatic improvement of at least one unit change in TDI focal score (test for subgroup differences: P = 0.62; <a href="./references#CD011594-fig-0014" title="">Analysis 1.8</a>). </p> </section> <section id="CD011594-sec-0083"> <h6 class="title">Change in lung function</h6> <p>Three trials assessed trough FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), two of which also reported one‐hour postmorning dose FEV<sub>1</sub> as the change from baseline in mean value at the end of the study (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). From the meta‐analysis of these data, we observed that FDC aclidinium/formoterol compared to aclidinium alone significantly improved both trough FEV<sub>1</sub> (MD 0.02, 95% CI 0.00 to 0.04; 3 trials, 2333 participants; high‐certainty evidence; <a href="./references#CD011594-fig-0015" title="">Analysis 1.9</a>; <a href="./full#CD011594-tbl-0001">summary of findings Table for the main comparison</a>) and postmorning dose FEV<sub>1</sub> (MD 0.10, 95% CI 0.08 to 0.12; 2 trials, 2018 participants; <a href="./references#CD011594-fig-0016" title="">Analysis 1.10</a>). Subgroup analysis for trough FEV<sub>1</sub> demonstrated a significant improvement compared to aclidinium alone with FDC dose containing formoterol 12 µg (MD 0.04, 95% CI 0.01 to 0.06; 3 trials, 1171 participants) and a non‐significant difference for FDC dose containing formoterol 6 µg (MD 0.01, 95% CI –0.02 to 0.04; 3 trials, 1162 participants). However, there was no evidence of a difference between the two doses of formoterol (test for subgroup differences: P = 0.16; <a href="./references#CD011594-fig-0015" title="">Analysis 1.9</a>). For postmorning dose FEV<sub>1</sub>, both FDC containing formoterol 12 µg (MD 0.12, 95% CI 0.09 to 0.15; 2 trials, 1013 participants) and formoterol 6 µg (MD 0.08, 95% CI 0.05 to 0.11; 2 trials, 1005 participants) produced a significant improvement compared with aclidinium alone (test for subgroup differences: P = 0.09; <a href="./references#CD011594-fig-0016" title="">Analysis 1.10</a>). </p> </section> <section id="CD011594-sec-0084"> <h6 class="title">Adverse events not including SAEs</h6> <p>From the pooled analysis of data of three trials, there was no evidence of a difference between FDC aclidinium/formoterol and aclidinium alone for the number of participants experiencing adverse events, not including SAEs (OR 0.95, 95% CI 0.76 to 1.18; 2473 participants; <a href="./references#CD011594-fig-0017" title="">Analysis 1.11</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). Both doses of formoterol 12 µg (OR 0.93, 95% CI 0.68 to 1.27; 3 trials, 1238 participants) and 6 µg (OR 0.97, 95% CI 0.71 to 1.31; 3 trials, 1235 participants) showed similar results (test for subgroup differences: P = 0.85, <a href="#CD011594-fig-0004">Figure 4</a>). In absolute terms, 186/1000 participants (95% CI 155 to 221) in the FDC aclidinium/formoterol group had adverse events compared with 194/1000 in the aclidinium alone group (moderate‐certainty evidence; <a href="./full#CD011594-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD011594-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.11 Number of participants with adverse events (not including serious adverse events)." data-id="CD011594-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.11 Number of participants with adverse events (not including serious adverse events). </p> </div> </div> </div> </section> </section> </section> <section id="CD011594-sec-0085"> <h4 class="title">2. Fixed‐dose combination aclidinium/formoterol versus formoterol alone</h4> <section id="CD011594-sec-0086"> <h5 class="title">Primary outcomes</h5> <section id="CD011594-sec-0087"> <h6 class="title">Exacerbations requiring a short course of an oral steroid or antibiotic, or both</h6> <p>Three trials reported exacerbations requiring a short course of an oral steroid or antibiotic, or both (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). Overall analysis of data from these trials demonstrated a statistically significant reduction in the number of participants experiencing at least one exacerbation requiring a short course of an oral steroid or antibiotic, or both, with FDC aclidinium/formoterol compared to formoterol alone (OR 0.78, 95% CI 0.62 to 0.99; 3 trials, 2694 participants; high‐certainty evidence; <a href="./references#CD011594-fig-0018" title="">Analysis 2.1</a>). In absolute terms, 124/1000 participants (95% CI 101 to 152) receiving FDC aclidinium/formoterol had at least one exacerbation compared to 154/1000 participants receiving formoterol alone; thus FDC aclidinium/formoterol resulted in 30 fewer (2 to 53 fewer) participants with a moderate exacerbation than formoterol alone (<a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>). Subgroup analysis showed that the difference between formoterol 12 µg (OR 0.75, 95% CI 0.56 to 1.00; 3 trials, 1622 participants) and formoterol 6 µg (OR 0.85, 95% CI 0.57 to 1.26; 2 trials, 1072 participants) was not statistically significant (test for subgroup differences: P = 0.64, <a href="#CD011594-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD011594-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Fixed‐dose combination (FDC) aclidinium and formoterol versus formoterol, Outcome: 2.1 Number of participants with exacerbations requiring steroids or antibiotics or both." data-id="CD011594-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Fixed‐dose combination (FDC) aclidinium and formoterol versus formoterol, Outcome: 2.1 Number of participants with exacerbations requiring steroids or antibiotics or both. </p> </div> </div> </div> </section> <section id="CD011594-sec-0088"> <h6 class="title">Quality of life</h6> <p>Two trials assessed quality of life reported as the change in mean SGRQ total score from baseline towards the end of the study (24 weeks) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>); however, <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> did not report the proportion of participants who attained a minimal clinically important difference of at least four units' reduction in the score. FDC aclidinium/formoterol revealed a statistically significant improvement in change from baseline in mean SGRQ total score with a mean difference of –1.88 compared to formoterol alone (95% CI –3.10 to –0.65; 2 trials, 2002 participants; <a href="./references#CD011594-fig-0019" title="">Analysis 2.2</a>); however, it found no significant improvement in the number of participants achieving at least four units reduction (OR 1.15, 95% CI 0.89 to 1.50; 1 trial, 1000 participants; <a href="./references#CD011594-fig-0020" title="">Analysis 2.3</a>). Further subgroup analysis indicated no significant improvement with formoterol 12 µg (MD –1.72, 95% CI –3.45 to 0.02; 2 trials, 1005 participants) and a significant reduction for FDC with formoterol 6 µg (MD –2.03, 95% CI –3.76 to –0.30; 2 trials, 997 participants); however, the difference was not significant between the two groups (test for subgroup differences: P = 0.80; <a href="./references#CD011594-fig-0019" title="">Analysis 2.2</a>). In a population of 1000, 559 (95% CI 495 to 623) participants taking FDC had at least a four‐unit reduction in SGRQ total score compared with 524 participants taking formoterol alone (low‐certainty evidence, <a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD011594-sec-0089"> <h6 class="title">Non‐fatal serious adverse events</h6> <p>Five trials reported participants with non‐fatal SAEs for FDC aclidinium/formoterol and formoterol alone, the pooled analysis of which showed no evidence of a difference between them (OR 1.15, 95% CI 0.82 to 1.61; 5 trials, 3140 participants; <a href="./references#CD011594-fig-0021" title="">Analysis 2.4</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). In a population of 1000, 58 (95% CI 42 to 79) participants in the FDC aclidinium/formoterol group and 50 participants in the formoterol alone group had a non‐fatal SAE (moderate‐certainty evidence; <a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>). The difference between FDCs containing formoterol 12 µg (OR 1.13, 95% CI 0.76 to 1.70; 5 trials, 1914 participants) and formoterol 6 µg (OR 1.20, 95% CI 0.65 to 2.20; 3 trials, 1226 participants) were not statistically significant (test for subgroup differences: P = 0.88). </p> </section> </section> <section id="CD011594-sec-0090"> <h5 class="title">Secondary outcomes</h5> <section id="CD011594-sec-0091"> <h6 class="title">Mortality</h6> <p>Five trials stated the number of deaths in published articles (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>); however, two of them reported no death during the study period (<a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). There was no evidence of a difference between FDC aclidinium/formoterol and formoterol alone for the all‐cause mortality (Peto OR 1.46, 95% CI 0.44 to 4.87; 5 trials, 3140 participants; <a href="./references#CD011594-fig-0022" title="">Analysis 2.5</a>). </p> </section> <section id="CD011594-sec-0092"> <h6 class="title">Hospital admissions due to exacerbations</h6> <p>Three trials assessed the number of participants with severe exacerbations requiring hospital admissions and the meta‐analysis found no difference between FDC aclidinium/formoterol and formoterol alone (OR 0.76, 95% CI 0.45 to 1.28; 2694 participants; <a href="./references#CD011594-fig-0023" title="">Analysis 2.6</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>). In a total of 1000 participants receiving FDC aclidinium/formoterol, 20 (95% CI 12 to 34) would require admission compared to 27 from the formoterol alone group (moderate‐certainty evidence; <a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>). Subgroup analysis showed no difference between an FDC formoterol dose of 12 µg (OR 0.69, 95% CI 0.38 to 1.25; 3 trials, 1622 participants) and formoterol 6 µg (OR 1.06, 95% CI 0.34 to 3.28; 2 trials, 1072 participants) (test for subgroup differences: P = 0.51). </p> </section> <section id="CD011594-sec-0093"> <h6 class="title">Improvement in symptoms</h6> <p>Two trials studied symptomatic improvement in terms of TDI focal score as change from baseline to the end of the study (24 weeks) as well as the percentage of participants who achieved a minimal clinically important difference of one unit improvement in the score (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). Overall, FDC aclidinium/formoterol was associated with a significant improvement in TDI focal score change from baseline compared with formoterol alone (MD 0.42, 95% CI 0.11 to 0.72; 2 trials, 2010 participants; <a href="./references#CD011594-fig-0024" title="">Analysis 2.7</a>). Subgroup analysis of the FDC formoterol dose of 12 µg found significant improvement (MD 0.47, 95% CI 0.03 to 0.90; 2 trials, 1011 participants) while formoterol 6 µg showed no significance (MD 0.37, 95% CI –0.06 to 0.80; 2 trials, 999 participants); however, test for subgroup differences was not significant (P = 0.76). </p> <p>Similarly, FDC aclidinium/formoterol was significantly associated with a higher number of participants achieving a clinically important improvement in TDI focal score (OR 1.30, 95% CI 1.07 to 1.56; 2 trials, 2010 participants; <a href="./references#CD011594-fig-0025" title="">Analysis 2.8</a>). In absolute terms, for every 1000 participants, 628 (95% CI 582 to 670; 17 more to 105 more) taking FDC aclidinium/formoterol and 565 taking formoterol alone attained a clinically significant symptomatic improvement (high‐certainty evidence, <a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>). Thus, for every 16 (95% CI 10 to 60) participants treated with FDC aclidinium/formoterol, one additional participant would attain the clinically important improvement of TDI focal score. Subgroup analysis of the dosage revealed no evidence of a difference between the subgroups (P = 0.57) of formoterol 12 µg (OR 1.23, 95% CI 0.94 to 1.60; 2 trials, 1011 participants) and formoterol 6 µg (OR 1.37, 95% CI 1.05 to 1.79; 2 trials, 999 participants). </p> </section> <section id="CD011594-sec-0094"> <h6 class="title">Change in lung function</h6> <p>Four trials reported change from baseline in trough FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), and two trials reported one‐hour postmorning dose FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). There was a significant improvement in trough FEV<sub>1</sub> change from baseline with FDC aclidinium/formoterol compared to formoterol alone (MD 0.04, 95% CI 0.03 to 0.06; 4 trials, 2411 participants; high‐certainty evidence; <a href="./references#CD011594-fig-0026" title="">Analysis 2.9</a>; <a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>). Both FDC formoterol dose of 12 µg (MD 0.05, 95% CI 0.03 to 0.08; 4 trials, 1254 participants) and formoterol 6 µg (MD 0.04, 95% CI 0.01 to 0.07; 3 trials, 1157 participants) had a statistically significant result with no difference between the two doses (test for subgroup differences: P = 0.52). </p> <p>FDC aclidinium/formoterol also resulted in a significant improvement of one‐hour postmorning dose FEV<sub>1</sub> compared with formoterol alone (MD 0.09, 95% CI 0.07 to 0.11; 2 trials, 2021 participants; <a href="./references#CD011594-fig-0027" title="">Analysis 2.10</a>). There was similar improvement for FDC dose of formoterol 12 µg (MD 0.11, 95% CI 0.08 to 0.14; 2 trials, 1015 participants) and formoterol 6 µg (MD 0.07, 95% CI 0.04 to 0.10; 2 trials, 1006 participants) with no evidence of a difference between the two doses (test for subgroup differences: P = 0.09). </p> </section> <section id="CD011594-sec-0095"> <h6 class="title">Adverse events not including SAEs</h6> <p>Analysis of data from five trials found significantly fewer adverse events (not including SAEs) with FDC aclidinium/formoterol compared to formoterol (OR 0.78, 95% CI 0.65 to 0.93; 5 trials, 3140 participants; <a href="./references#CD011594-fig-0028" title="">Analysis 2.11</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>; <a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). Upon subgroup analysis, there was no evidence of a difference between FDC dose of formoterol 12 µg (OR 0.79, 95% CI 0.63 to 0.99; 5 trials, 1914 participants) and formoterol 6 µg (OR 0.76, 95% CI 0.56 to 1.02; 3 trials, 1226 participants) with no evidence of a difference between the two doses (test for subgroup differences: P = 0.81). In a group of 1000 participants, 46 (95% CI 14 to 76 lower) fewer participants experienced adverse events if they received FDC aclidinium/formoterol compared to participants receiving formoterol alone (high‐certainty evidence; <a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>). Thus, to achieve an additional person with no adverse events, 22 (95% CI 13 to 71) participants need to be treated with FDC aclidinium/formoterol. </p> </section> </section> </section> <section id="CD011594-sec-0096"> <h4 class="title">3. Fixed‐dose combination aclidinium/formoterol versus placebo</h4> <section id="CD011594-sec-0097"> <h5 class="title">Primary outcomes</h5> <section id="CD011594-sec-0098"> <h6 class="title">Exacerbations requiring a short course of an oral steroid or antibiotic, or both</h6> <p>According to the analysis of data from two trials, FDC aclidinium/formoterol was not associated with significant reduction in the number of participants with exacerbations which required a short course of an oral steroid or antibiotic, or both, compared to placebo over the period of 24 weeks (moderate‐certainty evidence, OR 0.82, 95% CI 0.60 to 1.12; 2 trials, 1960 participants; <a href="./references#CD011594-fig-0029" title="">Analysis 3.1</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). Both FDCs containing formoterol 12 µg (OR 0.82, 95% CI 0.52 to 1.28; 2 trials; 983 participants) and formoterol 6 µg showed no significance over placebo (OR 0.82, 95% CI 0.53 to 1.27; 2 trials, 977 participants), with no difference among the doses (test for subgroup differences: P = 0.99). In absolute terms, among 1000 participants, FDC caused 20 fewer (47 lower to 14 higher) participants with moderate exacerbation requiring steroids or antibiotics, or both, than placebo (<a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD011594-sec-0099"> <h6 class="title">Quality of life</h6> <p>FDC aclidinium/formoterol produced a significant improvement in quality of life in terms of change from baseline in SGRQ total score (MD –2.91, 95% CI –4.33 to –1.50; 2 trials, 1823 participants; <a href="./references#CD011594-fig-0030" title="">Analysis 3.2</a>) as well as the number of participants with clinically important improvement of at least four units (OR 1.72, 95% CI 1.39 to 2.13; 2 trials, 1823 participants; <a href="./references#CD011594-fig-0031" title="">Analysis 3.3</a>) compared to placebo in two trials over 24 weeks (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). Both FDCs containing formoterol 12 µg (MD –2.86, 95% CI –4.87 to –0.85; 2 trials, 915 participants) and formoterol 6 µg (MD –2.97, 95% CI –4.97 to –0.96; 2 trials, 908 participants) showed significant improvement in SGRQ total score over placebo, with no difference among the doses (test for subgroup differences: P = 0.94, <a href="#CD011594-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD011594-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome: 3.2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score." data-id="CD011594-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome: 3.2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score. </p> </div> </div> </div> <p>Both FDCs with formoterol 12 µg (OR 1.69, 95% CI 1.26 to 2.28; 2 trials, 915 participants) and formoterol 6 µg (OR 1.75, 95% CI 1.29 to 2.36; 2 trials, 908 participants) revealed a significant number of participants with SGRQ total score of at least four units' improvement (test for subgroup differences: P = 0.89). Among a population of 1000 participants, 568 taking FDC had a clinically important improvement in SGRQ total score of more than four units whereas only 433 of those given placebo resulted in similar response (difference 135, 95% CI 82 to 186 more). Thus, for every seven (95% CI five to 12) participants treated with FDC aclidinium/formoterol, one extra person would achieve a clinically important improvement in quality of life compared to placebo (high‐certainty evidence; <a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD011594-sec-0100"> <h6 class="title">Non‐fatal serious adverse events</h6> <p>Four trials reported the number of participants with non‐fatal SAEs (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). There was no evidence of a difference between FDC aclidinium/formoterol and placebo (OR 1.12, 95% CI 0.72 to 1.74; 4 trials, 2527 participants; moderate‐certainty evidence; <a href="./references#CD011594-fig-0032" title="">Analysis 3.4</a>). There was no difference between FDCs with formoterol 12 µg (OR 1.15, 95% CI 0.63 to 2.10; 4 trials, 1399 participants) and formoterol 6 µg (OR 1.09, 95% CI 0.56 to 2.09; 3 trials, 1128 participants), with no evidence of a difference between the subgroups (P = 0.90). In a group of 1000 participants, 42 (95% CI 27 to 64) receiving FDC aclidinium/formoterol and 38 receiving placebo experienced a non‐fatal SAE (<a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> <section id="CD011594-sec-0101"> <h5 class="title">Secondary outcomes</h5> <section id="CD011594-sec-0102"> <h6 class="title">Mortality</h6> <p>Three studies found no difference in the number of deaths between FDC aclidinium/formoterol and placebo (Peto OR 3.79, 95% CI 0.37 to 39.13; 3 trials, 2260 participants; <a href="./references#CD011594-fig-0033" title="">Analysis 3.5</a>) (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). There were no reported deaths in <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>, which was a short duration study of four weeks. </p> </section> <section id="CD011594-sec-0103"> <h6 class="title">Hospital admissions due to exacerbations</h6> <p>Two studies reported hospital admissions due to exacerbations (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). There was no evidence of a difference in the number of participants with severe exacerbations who required hospital admissions between FDC aclidinium/formoterol and placebo (OR 0.55, 95% CI 0.25 to 1.18; 1960 participants; <a href="./references#CD011594-fig-0034" title="">Analysis 3.6</a>). Both FDCs with formoterol 12 µg (OR 0.49, 95% CI 0.15 to 1.60; 2 trials, 983 participants) and formoterol 6 µg (OR 0.59, 95% CI 0.21 to 1.65; 2 trials, 977 participants) revealed similar results, with no evidence of a difference between the subgroups (P = 0.83). In absolute terms, for a group of 1000 participants, 12 (95% CI 5 to 25) from the FDC aclidinium/formoterol group required hospitalisation due to exacerbations compared with 21 from the placebo group (moderate‐certainty evidence; <a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD011594-sec-0104"> <h6 class="title">Improvement in symptoms</h6> <p>Two studies reported improvement in symptoms (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). Compared to placebo, FDC aclidinium/formoterol showed significant improvement in terms of TDI focal score change from baseline over 24 weeks (MD 1.32, 95% CI 0.96 to 1.69; 1832 participants; <a href="./references#CD011594-fig-0035" title="">Analysis 3.7</a>). Both doses of FDC formoterol 12 µg (MD 1.37, 95% CI 0.85 to 1.88; 2 trials; 922 participants) and formoterol 6 µg (MD 1.28, 95% CI 0.77 to 1.80; 2 trials, 910 participants) showed significance over placebo with no difference between the two subgroups (P = 0.82). </p> <p>Likewise, FDC aclidinium/formoterol was associated with a significantly higher number of participants with a minimal clinically significant improvement of TDI focal score one unit or more when compared with placebo (OR 2.51, 95% CI 2.02 to 3.11; 2 trials, 1832 participants; <a href="./references#CD011594-fig-0036" title="">Analysis 3.8</a>). This significant improvement was observed with FDCs containing formoterol 12 µg (OR 2.37, 95% CI 1.75 to 3.22; 2 trials, 922 participants) and formoterol 6 µg (OR 2.65, 95% CI 1.96 to 3.60; 2 trials, 910 participants). There was no difference between the subgroups (P = 0.61). In a group of 1000 participants, 620 (95% CI 568 to 669) taking FDC aclidinium/formoterol had at least one unit increment in TDI focal score compared with 394 for placebo group over 24 weeks' duration (high‐certainty evidence; <a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>). One additional participant would achieve a minimal clinically significant increment of at least one unit in TDI focal score for every four (95% CI four to six) participants treated with FDC aclidinium/formoterol compared to placebo. </p> </section> <section id="CD011594-sec-0105"> <h6 class="title">Change in lung function</h6> <p>Three trials studied change from baseline in trough FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>), while two studies reported change from baseline in one‐hour post morning dose FEV<sub>1</sub> (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>). FDC aclidinium/formoterol significantly improved trough FEV<sub>1</sub> change from baseline compared with placebo (MD 0.12, 95% CI 0.10 to 0.14; 3 trials, 2137 participants; high‐certainty evidence; <a href="./references#CD011594-fig-0037" title="">Analysis 3.9</a>; <a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>). There was no difference between FDCs with formoterol 12 µg (MD 0.13, 95% CI 0.10 to 0.16; 3 trials, 1073 participants) and formoterol 6 µg (MD 0.11, 95% CI 0.07 to 0.14; 3 trials, 1064 participants; test for subgroup differences: P = 0.25). </p> <p>FDC aclidinium/formoterol also demonstrated a significant improvement in one‐hour postmorning dose FEV<sub>1</sub> change from baseline compared to placebo (MD 0.27, 95% CI 0.25 to 0.30; 2 trials, 1842 participants; <a href="./references#CD011594-fig-0038" title="">Analysis 3.10</a>) with no difference between FDCs with formoterol 12 µg (MD 0.29 , 95% CI 0.25 to 0.33; 2 trials, 925 participants) and formoterol 6 µg (MD 0.25, 95% CI 0.22 to 0.29; 2 trials, 917 participants; test for subgroup differences: P = 0.17). </p> </section> <section id="CD011594-sec-0106"> <h6 class="title">Adverse events not including SAEs</h6> <p>Four trials reported the number of participants experiencing adverse events not including SAEs (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>; <a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a>). There was no difference between FDC aclidinium/formoterol and placebo (OR 0.97, 95% CI 0.76 to 1.22; 2527 participants, moderate‐certainty evidence; <a href="./references#CD011594-fig-0039" title="">Analysis 3.11</a>). Both FDCs with formoterol 12 µg (OR 0.89, 95% CI 0.65 to 1.22; 4 trials, 1399 participants) and formoterol 6 µg (OR 1.07, 95% CI 0.75 to 1.53; 3 trials, 1128 participants) resulted in the similar response compared to placebo with no difference between the subgroups (P = 0.44). Out of 1000 participants, 171 (95% CI 139 to 206) in the FDC aclidinium/formoterol group would experience at least one adverse event compared with 175 for placebo group over a period of four to 24 weeks (<a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011594-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011594-sec-0107">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011594-sec-0171">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011594-sec-0107"></div> <section id="CD011594-sec-0108"> <h3 class="title" id="CD011594-sec-0108">Summary of main results</h3> <p>We could only identify trials assessing a combination therapy of aclidinium/formoterol in a single inhaler as an FDC with the dose of formoterol either 12 µg or 6 µg. Compared to aclidinium alone, FDC aclidinium/formoterol significantly improved symptoms as TDI focal score was increased by 0.37 units (from 0.07 to 0.68 higher) although this mean improvement did not reach the accepted threshold of one unit for a clinically important difference. Correspondingly, there was a significantly higher number of TDI responders with FDC aclidinium/formoterol than aclidinium alone, with an NNTB of 14. FDC aclidinium/formoterol also improved lung function, both trough FEV<sub>1</sub> and one‐hour postmorning dose FEV<sub>1</sub>, but there were no differences in terms of exacerbations requiring steroids, or antibiotics, or both; quality of life; hospital admissions due to severe exacerbations; all‐cause mortality; non‐fatal SAEs and other adverse events compared with aclidinium. </p> <p>When compared to formoterol alone, FDC aclidinium/formoterol demonstrated a significant improvement in symptoms; lung function; quality of life; reduction in exacerbations requiring a short course of steroids or antibiotics, or both and adverse events (not including SAEs). FDC aclidinium/formoterol was associated with a mean increase in TDI focal score of 0.42 units (from 0.11 to 0.72 higher) as well as a greater TDI responders than formoterol (NNTB 16). Combination therapy also lowered SGRQ total score by 1.88 units (from 3.10 to 0.65 lower) compared with formoterol, although this mean improvement did not reach clinical significance of four units. However, there was no difference for hospital admissions, all‐cause mortality and non‐fatal SAEs. </p> <p>In comparison with placebo, combination therapy significantly improved quality of life, symptoms and lung function. FDC aclidinium/formoterol demonstrated a clinically significant reduction of 2.91 units (from 4.33 to 1.50 lower) in SGRQ total score with an NNTB of seven. Participants treated with FDC aclidinium/formoterol experienced clinically significantly greater improvements in dyspnoea with a TDI focal score change from baseline of 1.32 units (95% CI 0.96 to 1.69 units) compared to placebo. To attain one additional person with at least one unit increase in TDI focal score, four participants need to be treated. There were no differences between combination therapy and placebo in terms of moderate exacerbations requiring steroids or antibiotics, or both; hospital admissions due to severe exacerbations; all‐cause mortality; adverse events and non‐fatal SAEs. </p> </section> <section id="CD011594-sec-0109"> <h3 class="title" id="CD011594-sec-0109">Overall completeness and applicability of evidence</h3> <p>The latest COPD guidelines recommend the use of combined LABA and LAMA as an alternative for people with group B and C COPD with persistent symptoms or further exacerbations and as a first line for people with group D COPD (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). An FDC of aclidinium 400 µg and formoterol 12 µg as Duaklir Genuair was approved by the European Medicines Agency in November 2014 for people with COPD. The evidence from this review arose from the meta‐analysis of six trials of moderate‐to‐high methodological standard, thus providing a better estimate of treatment effects on the risks and benefits of combination therapy than any of the studies alone. One of the included studies (<a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a>) was the extension study of <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>, and we included only the data of the primary study as the extension period was not a truly randomised comparison with substantial withdrawals. Some of the data required for the meta‐analysis were not reported in the published articles for which we contacted the manufacturers who were helpful in providing additional information. Most of the data in the published articles reported the difference in treatment effects versus monotherapies or placebo rather than the individual arms. Thus, we requested for exact values, which were provided for two studies (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>), or used the data provided by the ClinicalTrials website or participant level data from the AztraZeneca database for other trials to maximise the accuracy of our evidence. Clinical characteristics of the participants recruited into the trials, baseline severity of the disease and prior medications were similar between the trial arms. There was little or no heterogeneity for most of the summary estimates, except for the total number of deaths compared to aclidinium as there were more deaths among the FDC group; however, none of these was considered to be related to study medication as all these participants had multiple underlying comorbidities. In most of the studies, formoterol was delivered in Genuair inhaler to maintain blindness, which is not an ideal device and might affect the outcome measures for comparison with formoterol. In this review, subgroup analysis was performed for the dose of formoterol in the FDC, 12 µg or 6 µg, for most of the outcomes; however, there was no evidence of a difference between the subgroups. </p> <p>Generally, the evidence from this review supported the effectiveness of combination therapy compared to monotherapies and placebo for improving lung function and reducing dyspnoea for people with stable COPD which is in accordance with the updated GOLD recommendations (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). Based on the evidence from this review, aclidinium/formoterol combination therapy showed no difference in reducing exacerbations, either moderate exacerbations requiring short course of steroids or antibiotics, or both, or severe exacerbations requiring hospital admissions. There was a possibility of better reduction in moderate exacerbations which necessitated the use of steroids or antibiotics, or both, with FDC compared to formoterol, though the summary estimates may not be clinically significant. It could be due to power effect as the analysis involved three trials with more participants. For other comparisons, the data contributing to the exacerbation outcome came from only two trials of 24 weeks' duration and we strongly believe further inclusion of longer studies will alter this evidence. There was no difference in all‐cause mortality, adverse events and non‐fatal SAEs indicating the safety of this combination treatment. There were statistically fewer adverse events with FDC aclidinium/formoterol when compared to formoterol alone. Overall, the evidence from our review indicated that combination treatment was an effective and safe option for treating people with stable COPD. </p> </section> <section id="CD011594-sec-0110"> <h3 class="title" id="CD011594-sec-0110">Quality of the evidence</h3> <p>We evaluated the quality of evidence for the review's outcomes with GRADE assessment (<a href="./full#CD011594-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011594-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011594-tbl-0003">summary of findings Table 3</a>), which ranged from low to high. All the seven included studies in this review were industry sponsored and were conducted according to similar prespecified protocols with generally limited potential for significant bias. The meta‐analyses of most of the outcomes of this review were mainly contributed by two trials (<a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>; <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a>), and occasionally by other four trials. The studies providing data to this review were large and we judged them to be at low or unclear for overall risk of bias. All the comparisons for the outcomes were direct and there was no significant heterogeneity for most of the outcomes. In a few select instances for the comparison with formoterol alone, moderate statistical heterogeneity detected was difficult to explain, with trials having similar inclusion and exclusion criteria, enrolling participants with similar severity of disease and using similar methodology and statistical approaches. Most of the pooled effect estimates were not precise which led to downgrading of the evidence in our review. Improvement in symptoms and lung function were graded as high‐certainty evidence for all comparisons and we are confident that the true effect lies close to the effect estimate. We rated the certainty of evidence for improvement in SGRQ total score as high for the comparison of FDC aclidinium/formoterol with placebo, moderate for aclidinium and low for formoterol. In primary studies, some predefined endpoints especially exacerbations were not published specifically as moderate and severe exacerbations, although these outcomes of interest were made available by the manufacturer. However, we are less confident and certain about exacerbation and hospital admission outcomes for all comparisons. As these are relatively infrequent events for the current included trials of relatively short duration, additional information from future trials might alter our confidence in these results and provide new evidence for clinical practice. </p> </section> <section id="CD011594-sec-0111"> <h3 class="title" id="CD011594-sec-0111">Potential biases in the review process</h3> <p>We made every effort to obtain grey literature to minimise bias in the review process. In addition to the Cochrane Airways Group's systematic electronic search, we performed a comprehensive search of other sources including manufacturers' websites and trial registries. We also contacted the trial authors for missing data and were provided access to participant level data of the individual trials concerned. Two review authors independently determined inclusion and exclusion of trials, extracted data and judged risk of bias to minimise error. Most of the data were consistent throughout the published trials and ClinicalTrial.gov website except for the outcome for SGRQ responders in <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a>. We noted an inconsistency in the reporting of SGRQ responders as the number of responders did not appear to be compatible with the finding of overall improvement in SGRQ total score for formoterol and FDC aclidinium/formoterol arms. Inclusion of only seven studies in this review limited the use of a funnel plot for proper publication bias assessment. </p> <p>Most reported data were obtained from methodologically robust RCTs, and the potential for introduction of significant systematic biases in these trials is generally considered to be low. Clinical characteristics of the participants recruited into the trials and baseline disease severity were similar across the trials. Rates of attrition were generally between 10% and 20%, with higher rates in <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> and <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>. There was slightly greater loss of participants from placebo than experimental arms in <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> and in <a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a>, both FDC aclidinium/formoterol and formoterol alone arms had high withdrawal rates. Loss to follow‐up was most commonly due to unsatisfactory therapeutic effect or to adverse events or withdrawal of consent. Therefore, it is possible that unmatched attrition between placebo and experimental arms may have introduced some bias, and such bias would most likely lead to underestimation of the treatment effects of FDC. However, the overall impact of such bias was likely to be low as the analyses were based on the ITT population. </p> <p>Concomitant use of ICSs and methylxanthines may impact outcomes; however, inclusion of only the participants who had already achieved a stable state with these medications for at least four weeks prior to screening would have little influence on the overall effect estimates. It is also supported by the findings from a subgroup analysis of pooled data from <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> and <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> according to concomitant ICS use, in which aclidinium/formoterol 400/12 µg improved lung function compared with placebo and monotherapies regardless of ICS use (<a href="./references#CD011594-bbs2-0043" title="D'UrzoA , SinghD , Garcia GilE . Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD. Primary Care Respiratory Journal2017;27(1):13. [PUBMED: 28235977] ">D'Urzo 2017b</a>). In addition, prior use of LABAs, LAMAs, ICSs or combinations of any of these could also introduce bias; however, we noted no obvious differences between the proportions of participants treated with either of these agents in the intervention and control arms of included studies. Thus, we assume there will not be a significant change in the findings of our review. </p> </section> <section id="CD011594-sec-0112"> <h3 class="title" id="CD011594-sec-0112">Agreements and disagreements with other studies or reviews</h3> <p>There has been increasing evidence that LABA/LAMA combination therapy is more efficacious than monotherapies or placebo for improving symptoms, lung function and quality of life, and reducing exacerbations. To date, despite a considerable number of meta‐analyses and systematic reviews on combined LABA/LAMA therapy, those focusing specifically on aclidinium and formoterol are limited. In one systematic review of an indirect comparison between aclidinium/formoterol and tiotropium (<a href="./references#CD011594-bbs2-0067" title="MedicG , LindnerL , van derWeijdenM , KarabisA . Efficacy and safety of aclidinium/formoterol versus tiotropium in COPD: results of an indirect treatment comparison. Advances in Therapy2016;33(3):379‐99. [PUBMED: 26883661] ">Medic 2016</a>), combined therapy was more effective than tiotropium alone in improving FEV<sub>1</sub> and dyspnoea with correspondingly higher number of TDI responders. There was no difference for quality of life, hospitalisations, adverse events and SAEs. <a href="./references#CD011594-bbs2-0028" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. [PUBMED: 26233481] ">Bateman 2015</a> and <a href="./references#CD011594-bbs2-0045" title="DiMarcoF , SantusP , ScichiloneN , SolidoroP , ContoliM , BraidoF , et al. Symptom variability and control in COPD: advantages of dual bronchodilation therapy. Respiratory Medicine2017;125:49‐56. [PUBMED: 28340862] ">Di Marco 2017</a> reported that FDC aclidinium/formoterol 400/12 μg therapy significantly improved TDI focal score compared to monotherapies and placebo with the potential to control symptoms throughout the 24 hours, which was similar to our findings. That review also revealed a significant reduction in moderate‐to‐severe exacerbations versus placebo but not the monotherapies, a finding our review did not demonstrate. Our review's finding of FEV<sub>1</sub> improvement and dyspnoea reduction by FDC aclidinium/formoterol also supports the 2018 updated GOLD guidance (<a href="./references#CD011594-bbs2-0054" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2018 report). www.goldcopd.org/ (accessed 11 February 2018). ">GOLD 2018</a>). </p> <p>Current evidence suggests that LABA/LAMA therapy was more effective than monotherapy in terms of symptoms, quality of life and lung function (<a href="./references#CD011594-bbs2-0034" title="CalzettaL , RoglianiP , OraJ , PuxedduE , CazzolaM , MateraMG . LABA/LAMA combination in COPD: a meta‐analysis on the duration of treatment. European Respiratory Review2017;26:143. [PUBMED: 28096283] ">Calzetta 2017a</a>; <a href="./references#CD011594-bbs2-0062" title="LalC , StrangeC . A review of current and developing fixed‐dose LABA/LAMA combinations for treating COPD. Expert Opinion on Pharmacotherapy2017;18(17):1833‐43. [PUBMED: 29115881] ">Lal 2017</a>; <a href="./references#CD011594-bbs2-0077" title="ObaY , SarvaST , DiasS . Efficacy and safety of long‐acting beta‐agonist/long‐acting muscarinic antagonist combinations in COPD: a network meta‐analysis. Thorax2016;71(1):15‐25. [PUBMED: 26490732] ">Oba 2016</a>; <a href="./references#CD011594-bbs2-0085" title="RodrigoGJ , PriceD , AnzuetoA , SinghD , AltmanP , BaderG , et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta‐analysis. International Journal of Chronic Obstructive Pulmonary Disease2017;12:907‐22. [PUBMED: 28360514] ">Rodrigo 2017</a>), though our review did not show an improvement in HRQoL versus aclidinium. In another meta‐analysis, LABA/LAMA combinations were significantly more effective than LABA or LAMA alone in terms of improvement in endurance time and inspiratory capacity (<a href="./references#CD011594-bbs2-0035" title="CalzettaL , OraJ , CavalliF , RoglianiP , O'DonnellDE , CazzolaM . Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair‐wise and network meta‐analysis. Respiratory Medicine2017;129:189‐98. [PUBMED: 28732830] ">Calzetta 2017b</a>), though the studies particularly comparing FDC aclidinium/formoterol with monotherapy were not included in that analysis. In our review, people taking FDC aclidinium/formoterol had fewer exacerbations requiring steroids or antibiotics, or both than formoterol alone but not when compared with aclidinium alone, which is a comparable finding as in the network meta‐analysis by <a href="./references#CD011594-bbs2-0077" title="ObaY , SarvaST , DiasS . Efficacy and safety of long‐acting beta‐agonist/long‐acting muscarinic antagonist combinations in COPD: a network meta‐analysis. Thorax2016;71(1):15‐25. [PUBMED: 26490732] ">Oba 2016</a>. Variable degree of symptoms at baseline possibly could affect our findings of lung function and symptomatic improvement; however, the baseline characteristics of participants are comparable among the groups. One post hoc pooled analysis of <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> and <a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> categorised by symptom status demonstrated a similar magnitude of postdose FEV<sub>1</sub> improvements regardless of the baseline symptoms. Not surprisingly, greater improvement in trough FEV<sub>1</sub> from baseline and dyspnoea was observed in more symptomatic participants (<a href="./references#CD011594-bbs2-0068" title="MiravitllesM , ChapmanKR , ChuecosF , RiberaA , GilEG . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11:2041‐53. [PUBMED: 27621610] ">Miravitlles 2016</a>). According to the long‐term studies over a five‐year period conducted in Scotland (<a href="./references#CD011594-bbs2-0080" title="RamosM , HaughneyJ , HenryN , LindnerL , LamotteM . Cost versus utility of aclidinium bromide 400 microg plus formoterol fumarate dihydrate 12 microg compared to aclidinium bromide 400 microg alone in the management of moderate‐to‐severe COPD. ClinicoEconomics and Outcomes Research2016;8:445‐56. [PUBMED: 27672337] ">Ramos 2016</a>) and Spain (<a href="./references#CD011594-bbs2-0036" title="CapelM , MarequeM , AlvarezCJ , LindnerL , OyaguezI . Cost‐effectiveness of fixed‐dose combinations therapies for chronic obstructive pulmonary disease treatment. Clinical Drug Investigation2018;38(7):611‐20. [PUBMED: 29654555] ">Capel 2018</a>), combined therapy of FDC aclidinium/formoterol 400/12 μg can be considered a cost‐effective option compared to aclidinium 400 μg alone or tiotropium/olodaterol in people with moderate‐to‐severe COPD though our review did not assess the cost of these medications. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011594-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score." data-id="CD011594-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.11 Number of participants with adverse events (not including serious adverse events)." data-id="CD011594-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fixed‐dose combination (FDC) aclidinium and formoterol versus aclidinium, Outcome: 1.11 Number of participants with adverse events (not including serious adverse events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Fixed‐dose combination (FDC) aclidinium and formoterol versus formoterol, Outcome: 2.1 Number of participants with exacerbations requiring steroids or antibiotics or both." data-id="CD011594-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Fixed‐dose combination (FDC) aclidinium and formoterol versus formoterol, Outcome: 2.1 Number of participants with exacerbations requiring steroids or antibiotics or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome: 3.2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score." data-id="CD011594-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome: 3.2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 1 Exacerbations requiring steroids or antibiotics or both: number of participants." data-id="CD011594-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 1 Exacerbations requiring steroids or antibiotics or both: number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score." data-id="CD011594-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 3 Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score." data-id="CD011594-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 3 Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 4 Non‐fatal serious adverse events." data-id="CD011594-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 4 Non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 5 Total number of deaths." data-id="CD011594-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 5 Total number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 6 Hospital admissions due to exacerbations: number of participants." data-id="CD011594-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 6 Hospital admissions due to exacerbations: number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score." data-id="CD011594-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)." data-id="CD011594-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV1) (L)." data-id="CD011594-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 10 Change in lung function: from baseline in 1‐hour postmorning dose FEV1 (L)." data-id="CD011594-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 10 Change in lung function: from baseline in 1‐hour postmorning dose FEV<sub>1</sub> (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-001-11.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 11 Adverse events (not including serious adverse events): number of participants." data-id="CD011594-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium, Outcome 11 Adverse events (not including serious adverse events): number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 1 Exacerbations requiring steroids or antibiotics or both: number of participants." data-id="CD011594-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 1 Exacerbations requiring steroids or antibiotics or both: number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score." data-id="CD011594-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 3 Quality of life: Number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score." data-id="CD011594-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 3 Quality of life: Number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 4 Non‐fatal serious adverse events." data-id="CD011594-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 4 Non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 5 Total number of deaths." data-id="CD011594-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 5 Total number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 6 Hospital admissions due to exacerbations: number of participants." data-id="CD011594-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 6 Hospital admissions due to exacerbations: number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score." data-id="CD011594-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)." data-id="CD011594-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV1) (L)." data-id="CD011594-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 10 Change lung function: from baseline in 1‐hour postmorning dose FEV1 (L)." data-id="CD011594-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 10 Change lung function: from baseline in 1‐hour postmorning dose FEV<sub>1</sub> (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 11 Adverse events (not including serious adverse events): number of participants." data-id="CD011594-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol, Outcome 11 Adverse events (not including serious adverse events): number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 1 Exacerbations requiring steroids or antibiotics or both: number of participants." data-id="CD011594-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 1 Exacerbations requiring steroids or antibiotics or both: number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score." data-id="CD011594-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 3 Quality of life: Number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score." data-id="CD011594-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 3 Quality of life: Number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 4 Non‐fatal serious adverse events." data-id="CD011594-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 4 Non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 5 Total number of deaths." data-id="CD011594-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 5 Total number of deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 6 Hospital admissions due to exacerbations: number of participants." data-id="CD011594-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 6 Hospital admissions due to exacerbations: number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score." data-id="CD011594-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)." data-id="CD011594-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV1) (L)." data-id="CD011594-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 10 Change lung function: from baseline in 1‐hour postmorning dose FEV1 (L)." data-id="CD011594-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 10 Change lung function: from baseline in 1‐hour postmorning dose FEV<sub>1</sub> (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011594-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/urn:x-wiley:14651858:media:CD011594:CD011594-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_t/tCD011594-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 11 Adverse events (not including serious adverse events): number of participants." data-id="CD011594-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo, Outcome 11 Adverse events (not including serious adverse events): number of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/media/CDSR/CD011594/image_n/nCD011594-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011594-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to aclidinium alone for chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fixed‐dose combination aclidinium/formoterol compared to aclidinium for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> FDC aclidinium/formoterol<br/> <b>Comparison:</b> aclidinium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with aclidinium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FDC aclidinium/formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids or antibiotics or both: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (77 to 130) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.95</b><br/> (0.71 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2156<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>541 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>579 per 1000<br/> (533 to 624) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.17</b><br/> (0.97 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2002<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: change from baseline in SGRQ total score was 0.92 lower (2.15 lower to 0.3 higher) in FDC group (2002 participants, 2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (33 to 72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.19</b><br/> (0.79 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2473<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (5 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.62</b><br/> (0.29 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2156<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)</b> <br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>557 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>627 per 1000<br/> (582 to 671) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.34</b><br/> (1.11 to 1.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms: change from baseline in TDI focal score was 0.37 higher (0.07 higher to 0.68 higher) in FDC group (2013 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in lung function: from baseline in trough FEV<sub>1</sub> (L)</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) across aclidinium group ranged from –0.017 to 0.066 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) in the FDC group was 0.02 higher (0 to 0.04 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2333<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (not including serious adverse events): number of participants</b> </p> <p>Follow‐up: 4–24 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000<br/> (155 to 221) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.95</b><br/> (0.76 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2473<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FDC:</b> fixed‐dose combination; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>TDI:</b> Transitional Dyspnoea Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision: the CIs included a potential for appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to aclidinium alone for chronic obstructive pulmonary disease (COPD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011594-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to formoterol for chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fixed‐dose combination aclidinium/ formoterol compared to formoterol for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with COPD<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> FDC aclidinium/formoterol<br/> <b>Comparison:</b> formoterol </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with formoterol</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FDC aclidinium/formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids or antibiotics or both: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>124 per 1000<br/> (101 to 152) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b><br/> (0.62 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2694<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>524 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>559 per 1000<br/> (495 to 623) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.15</b><br/> (0.89 to 1.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: change from baseline in SGRQ total score was 1.88 lower (3.1 lower to 0.65 lower) in FDC group (2002 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b><br/> Follow‐up: 4–52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (42 to 79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.15</b><br/> (0.82 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3140<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations: number of participants</b><br/> Follow‐up: 24–52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (12 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.76</b><br/> (0.45 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2694<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>565 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000<br/> (582 to 670) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.30</b><br/> (1.07 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2010<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms: change from baseline in TDI focal score was 0.42 higher (0.11 higher to 0.72 higher) in FDC group (2010 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in lung function: from baseline in trough FEV<sub>1</sub> (L)</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) across formoterol group ranged from –0.002 to 0.118 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) in the FDC group was 0.04 higher (0.03 higher to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2411<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (not including serious adverse events): number of participants</b><br/> Follow‐up: 4–52 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>271 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/> (195 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b><br/> (0.65 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3140<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FDC:</b> fixed‐dose combination; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>TDI:</b> Transitional Dyspnoea Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision: CIs included a potential for appreciable benefit or harm. </p> <p><sup>b</sup>Downgraded one level as <a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> did not report the SGRQ responders for formoterol arm in the published articles. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to formoterol for chronic obstructive pulmonary disease (COPD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011594-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to placebo for chronic obstructive pulmonary disease (COPD)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fixed dose combination aclidinium/formoterol compared to placebo for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with chronic obstructive pulmonary disease (COPD)<br/> <b>Setting:</b> community<br/> <b>Intervention:</b> FDC aclidinium/formoterol<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with FDC aclidinium/formoterol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations requiring steroids or antibiotics or both: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<br/> (82 to 143) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b><br/> (0.60 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1960<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>568 per 1000<br/> (515 to 619) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.72</b><br/> (1.39 to 2.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1823<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life: change from baseline in SGRQ total score was 2.91 lower (4.33 lower to 1.5 lower) in FDC group (1823 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal serious adverse events</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/> (27 to 64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.12</b><br/> (0.72 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2527<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admissions due to exacerbations: number of participants</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (5 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.55</b><br/> (0.25 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1960<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit)</b><br/> Follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000<br/> (568 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.51</b><br/> (2.02 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1832<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms: change from baseline in TDI focal score was 1.32 higher (0.96 higher to 1.69 higher) in FDC group (1832 participants, 2 RCTs). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in lung function: from baseline in trough FEV<sub>1</sub> (L)</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) across placebo group ranged from –0.061 to –0.031 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change from baseline in trough FEV<sub>1</sub> (L) in the FDC group was 0.12 higher (0.10 higher to 0.14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2137<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events (not including serious adverse events): number of participants</b><br/> Follow‐up: 4–24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/> (139 to 206) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.97</b><br/> (0.76 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2527<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>FDC:</b> fixed‐dose combination; <b>FEV<sub>1</sub>:</b> forced expiratory volume in 1 second; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SGRQ:</b> St George's Respiratory Questionnaire; <b>TDI:</b> Transitional Dyspnoea Index. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious imprecision: the CIs included a potential for appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fixed‐dose combination aclidinium/formoterol compared to placebo for chronic obstructive pulmonary disease (COPD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011594-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0001" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. EUCTR2011‐001524‐38‐GB . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐001524‐38‐GB Date first received: 5 July 2011. JonesPW , SinghD , BatemanED , KornS , SerraC , MolinsE , et al. The effect of aclidinium/formoterol fixed‐dose combination on COPD symptoms and health status in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A3764. [CENTRAL: 1035574; CRS: 4900126000023083] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01462942 . Long­term efficacy and safety of aclidinium/formoterol fixed­dose combination. clinicaltrials.gov/ct2/show/NCT01462942 Date first received: 1 November 2011. SinghD , JonesPW , BatemanE , KornS , SerraC , MolinsE , et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed‐dose combination in patients with COPD: the ACLIFORM study. Chest2014;145(3 Suppl):375A. [EMBASE: 71428958; PUBMED: 24638533] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Aclidinium/formoterol fixed‐dose combination improves bronchodilation and is well tolerated in patients with COPD: results from the ACLIFORM/COPD study. American Journal of Respiratory and Critical Care Medicine2014;189:A5987. [CENTRAL: 1035630; CRS: 4900126000023141] SinghD , JonesPW , BatemanED , KornS , SerraC , MolinsE , et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed‐dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM‐COPD): a multicentre, randomised study. BMC Pulmonary Medicine2014;14(1):178. [PUBMED: 25404569] ">ACLIFORM COPD</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1729</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg twice daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 400 μg twice daily</p> <p>Inhaled formoterol 12 μg twice daily</p> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0002" title="AymerichJG , WatzH , BeehKM , PaggiaroP , MoyaM , NotariM , et al. Use of the daily PROactive instrument to evaluate physical activity in patients with COPD: results from ACTIVATE. European Respiratory Journal2017; Vol. 50, issue Suppl 61:PA4964. EUCTR2014‐005318‐50‐HU . A multiple dose, randomised, double‐blind, placebo controlled, parallel clinical trial to assess the effect of aclidinium bromide/formoterol fumarate fixed‐dose combination on lung hyperinflation, exercise capacity and physical activity in patients with moderate to severe chronic obstructive pulmonary disease (COPD). ACTIVATE. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐005318‐50‐HU Date first received: 2 March 2015. NCT02424344 . Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in moderate to severe COPD patients. clinicaltrials.gov/ct2/show/NCT02424344 Date first received: 23 April 2015. WatzH , TroostersT , BeehKM , AymerichJG , PaggiaroP , MolinsE , et al. Effect of aclidinium/formoterol on lung hyperinflation, exercise capacity and physical activity in patients with COPD: results from ACTIVATE: a phase IV study. American Journal of Respiratory and Critical Care Medicine2017;195:A3593. WatzH , TroostersT , BeehKM , Garcia AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: effect of aclidinium/formoterol on physical activity in patients with COPD. European Respiratory Journal2017; Vol. 50:PA687. WatzH , TroostersT , BeehKM , Garcia‐AymerichJ , PaggiaroP , MolinsE , et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease2017;12:2545‐58. ">ACTIVATE</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0003" title="BatemanED , ChapmanKR , SinghD , D'UrzoAD , MolinsE , LeselbaumA , et al. Aclidinium bromide and formoterol fumarate as a fixed‐dose combination in COPD: pooled analysis of symptoms and exacerbations from two six‐month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respiratory Research2015;16:92. D'UrzoA , MergelV , LeselbaumA , CaractaC . Efficacy and safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with COPD: results from the AUGMENT COPD trial. Chest2013;144(4):1025A. [EMBASE: 71270077] D'UrzoA , RennardS , KerwinE , MergelV , HeT , LeselbaumA , et al. One‐year efficacy of aclidinium/formoterol fixed‐dose combination in COPD patients: the AUGMENT COPD study. European Respiratory Journal2014;44(Suppl 58):P286. D'UrzoA , RennardS , MergelV , Garcia GilE , LeselbaumA , CaractaC . The AUGMENT COPD trial: efficacy and safety of a fixed‐dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest2014;145(3 Suppl):426A. [EMBASE: 71429003; PUBMED: 24638583] D'UrzoAD , RennardSI , KerwinEM , HeT , LeselbaumA , CaractaC . Efficacy of fixed‐dose combination aclidinium bromide/formoterol fumarate on bronchodilation over 1 year: AUGMENT COPD extension trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6006. [CENTRAL: 1035555; CRS: 4900126000023064] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumA , CaractaC . Twice‐daily aclidinium bromide/formoterol fumarate fixed‐dose combination: lung function improvements in the AUGMENT COPD trial in patients with moderate to severe COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A3776. [CENTRAL: 1035556; CRS: 4900126000023065] D'UrzoAD , RennardSI , KerwinEM , MergelV , LeselbaumAR , CaractaC . Efficacy and safety of fixed‐dose combinations of aclidinium bromide/formoterol fumarate: the 24‐week, randomised, placebo‐controlled AUGMENT COPD study. Respiratory Research2014;15:123. [PUBMED: 25756831] D'UrzoAD , SinghD , KerwinE , LakkisH , ChuecosF , DeMiquelG . Efficacy and safety of aclidinium/formoterol fixed‐dose combination in patients with moderate to severe airflow obstruction, stratified by severity. European Respiratory Journal2015;46:PA1499. [DOI: 10.1183/13993003.congress‐2015.PA1499] MiravitllesM , ChapmanKR , ChuecosF , RiberaA , Garcia GilE . The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorised by symptom status: a pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease2016;11(1):2041‐52. MiravitllesM , Garcia GilE , ChuecosF , LamarcaR . Morning and night time symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. European Respiratory Journal2015;46:OA1968. [DOI: 10.1183/13993003.congress‐2015.OA1968] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 20 September 2011. [CRS: 4900101000003212] NCT01437397 . Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). clinicaltrials.gov/ct2/show/NCT01437397 Date first received: 23 March 2017. [CRS: 4900101000003154] RennardSI , D'UrzoAD , JonesPW , MergelV , LeselbaumA , CaractaC . Fixed‐dose combination of aclidinium bromide/formoterol fumarate improve breathlessness and health status in COPD patients: AUGMENT COPD trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6007. [CENTRAL: 1035618; CRS: 4900126000023127] ">AUGMENT COPD</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1692</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg twice daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 400 μg twice daily</p> <p>Inhaled formoterol 12 μg twice daily</p> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0004" title="D'UrzoA , RennardS , KerwinE , DonohueJF , LeiA , MolinsE , et al. A randomised double‐blind, placebo‐controlled, long‐term extension study of the efficacy, safety and tolerability of fixed‐dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respiratory Medicine2017;125:39‐48. [PUBMED: 28340861] MakeB , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed‐dose combination in patients with COPD: a one‐year study. European Respiratory Journal2014;44(Suppl 58):P2413. NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003214] NCT01572792 . Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28‐weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT01572792 Date first received: 6 April 2012. [CRS: 4900101000003158] RennardSI , D'UrzoAD , DonohueJF , HeT , ShresthaP , LeselbaumA , et al. Long‐term safety of fixed‐dose combination aclidinium bromide/formoterol fumarate in patients with moderate to severe COPD: the AUGMENT COPD extension trial. American Journal of Respiratory and Critical Care Medicine2014;189:A6008. [CENTRAL: 1035617; CRS: 4900126000023126] ">D'Urzo 2017a</a> </p> <p>(extension study of AUGMENT COPD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>921</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg twice daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 400 μg twice daily</p> <p>Inhaled formoterol 12 μg twice daily</p> <p>Inhaled placebo twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0005" title="DonohueJF , SoongW , WuX , ShresthaP , LeiA . Long‐term safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a randomised one‐year trial inpatients with COPD. Respiratory Medicine2016;116:41‐8. [DOI: 10.1016/j.rmed.2016.05.007] MakeB , DonohueJ , ZhongX , LeselbaumA , CaractaC . Long‐term safety of a fixed‐dose combination of aclidinium bromide/formoterol fumarate in patients with stable moderate to severe COPD. Chest2014;145(3 Suppl):386A. [EMBASE: 71428967; PUBMED: 24638543] MakeBJ , DonohueJF , SoongW , ZhongX , LeselbaumA , CaractaC . Lung function and safety of aclidinium bromide/formoterol fumarate fixed‐dose combination: results of a one‐year trial in patients with COPD. American Journal of Respiratory and Critical Care Medicine2014;189:A6010. [CENTRAL: 1035588; CRS: 4900126000023097] NCT01437540 . Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). clinicaltrials.gov/ct2/show/NCT01437540 Date first received: 21 September 2011. ">Donohue 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/12 μg twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled formoterol 12 μg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0006" title="NCT00706914 . Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/ct2/show/NCT00706914 Date first received: 30 June 2008. [CRS: 4900120000000479] ">NCT00706914</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 200/12 μg once daily in the morning and placebo once daily in the evening </p> <p>Inhaled FDC aclidinium/formoterol 200/12 μg once daily in the morning and formoterol 12 μg once daily in the evening </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled formoterol 12 μg twice daily</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011594-bbs2-0007" title="EUCTR2007‐004435‐30‐CZ . A randomised, four‐week, placebo‐controlled, double‐blind, six arm parallel group, dose‐finding clinical trial, to assess the efficacy and safety of three different doses of formoterol (6, 12 &amp; 18 µg) combined with the inhaled anticholinergic aclidinium bromide 200 µg, aclidinium bromide 200 µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe chronic obstructive pulmonary disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007‐004435‐30‐CZ Date first received: 10 December 2007. [CRS: 4900120000000461] NCT00626522 . Aclidinium/formoterol fixed combination dose finding study. clinicaltrials.gov/ct2/show/NCT00626522 Date first received: 29 February 2008. SliwinskiP , PerngD‐W , ChuchalinA , JonesPW . Efficacy and safety of once‐daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD. Thorax2010;65(Suppl IV):A136. [CENTRAL: 783128; CRS: 4900100000026295; EMBASE: 70325994] ">Sliwinski 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>566</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled FDC aclidinium/formoterol 400/6 μg once daily</p> <p>Inhaled FDC aclidinium/formoterol 400/12 μg once daily</p> <p>Inhaled FDC aclidinium/formoterol 400/18 μg once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled aclidinium 200 μg once daily</p> <p>Inhaled formoterol 12 μg once daily</p> <p>Inhaled placebo once daily</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>FDC: fixed‐dose combination.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/full#CD011594-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011594-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations requiring steroids or antibiotics or both: number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.71, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.60, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.65, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐2.15, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐2.51, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐2.81, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.97, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.86, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.93, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.79, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.74, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.60, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.14, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hospital admissions due to exacerbations: number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.29, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.19, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1076</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.24, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.07, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [‐0.01, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.10, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.11, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.98, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.08, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change in lung function: from baseline in 1‐hour postmorning dose FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.08, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.09, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.05, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events (not including serious adverse events): number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.71, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fixed‐dose combination (FDC) aclidinium/formoterol versus aclidinium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011594-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations requiring steroids or antibiotics or both: number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.56, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.88 [‐3.10, ‐0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.72 [‐3.45, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.03 [‐3.76, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: Number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.89, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.87, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.73, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.82, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.76, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.65, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.44, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hospital admissions due to exacerbations: number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.45, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.34, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.11, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.03, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [‐0.06, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.07, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.94, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.05, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.03, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.03, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change lung function: from baseline in 1‐hour postmorning dose FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.07, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.08, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.04, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events (not including serious adverse events): number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.65, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.63, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fixed‐dose combination (FDC) aclidinium/formoterol versus formoterol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011594-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations requiring steroids or antibiotics or both: number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.60, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.52, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.53, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life: change from baseline in St George's Respiratory Questionnaire (SGRQ) total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.91 [‐4.33, ‐1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.86 [‐4.87, ‐0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.97 [‐4.97, ‐0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quality of life: Number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.39, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.26, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.29, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.72, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.63, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.56, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total number of deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.79 [0.37, 39.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Hospital admissions due to exacerbations: number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.25, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.15, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.21, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Improvement in symptoms: change from baseline in Transitional Dyspnoea Index (TDI) focal score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.96, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.85, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.77, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [2.02, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.75, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [1.96, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in lung function: from baseline in trough forced expiratory volume in 1 second (FEV<sub>1</sub>) (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.10, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.10, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.07, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change lung function: from baseline in 1‐hour postmorning dose FEV<sub>1</sub> (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.25, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.25, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.22, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events (not including serious adverse events): number of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Formoterol 12 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.65, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Formoterol 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.75, 1.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fixed‐dose combination (FDC) aclidinium and formoterol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011594.pub2/references#CD011594-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011594.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011594-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011594-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011594-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011594-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011594-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011594-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011594\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011594\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011594\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011594\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011594\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011594.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011594.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011594.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011594.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011594.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727269188"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011594.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727269192"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011594.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea7ef7c159377',t:'MTc0MDcyNzI2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 